Document and Entity Information
Document and Entity Information - USD ($) $ in Billions | 12 Months Ended | ||
Dec. 31, 2021 | Feb. 15, 2022 | Jun. 30, 2021 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2021 | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Trading Symbol | CHD | ||
Entity Registrant Name | CHURCH & DWIGHT CO., INC. | ||
Entity Central Index Key | 0000313927 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Common Stock, Shares Outstanding | 242,691,649 | ||
Entity Public Float | $ 20.2 | ||
Title of 12(b) Security | Common Stock, $1 par value | ||
Security Exchange Name | NYSE | ||
Entity File Number | 1-10585 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 13-4996950 | ||
Entity Address, Address Line One | 500 Charles Ewing Boulevard | ||
Entity Address, City or Town | Ewing | ||
Entity Address, State or Province | NJ | ||
Entity Address, Postal Zip Code | 08628 | ||
City Area Code | 609 | ||
Local Phone Number | 806-1200 | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Auditor Name | DELOITTE & TOUCHE LLP | ||
Auditor Location | Parsippany, NJ | ||
Auditor Firm ID | 34 | ||
Documents Incorporated by Reference | Documents Incorporated by Reference Certain provisions of the registrant’s definitive proxy statement to be filed not later than April 30, 2022 are incorporated by reference in Items 10 through 14 of Part III of this Annual Report on Form 10‑K (this “Annual Report”). |
CONSOLIDATED STATEMENTS OF INCO
CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Statement [Abstract] | |||
Net Sales | $ 5,190.1 | $ 4,895.8 | $ 4,357.7 |
Cost of sales | 2,926.6 | 2,681.6 | 2,373.7 |
Gross Profit | 2,263.5 | 2,214.2 | 1,984 |
Marketing expenses | 577.7 | 591.2 | 515 |
Selling, general and administrative expenses | 606.7 | 593.3 | 628.8 |
Income from Operations | 1,079.1 | 1,029.7 | 840.2 |
Equity in earnings of affiliates | 9.4 | 6.7 | 6.6 |
Investment earnings | 0 | 0.5 | 1.6 |
Other income (expense), net | (2.3) | (2.1) | (1.1) |
Interest expense | (54.5) | (61) | (73.6) |
Income before Income Taxes | 1,031.7 | 973.8 | 773.7 |
Income taxes | 204.2 | 187.9 | 157.8 |
Net Income | $ 827.5 | $ 785.9 | $ 615.9 |
Weighted average shares outstanding - Basic | 244.9 | 246.8 | 246.2 |
Weighted average shares outstanding - Diluted | 249.6 | 252.2 | 252.1 |
Net income per share - Basic | $ 3.38 | $ 3.18 | $ 2.50 |
Net income per share - Diluted | 3.32 | 3.12 | 2.44 |
Cash dividends per share | $ 1.01 | $ 0.96 | $ 0.91 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Statement Of Income And Comprehensive Income [Abstract] | |||
Net Income | $ 827.5 | $ 785.9 | $ 615.9 |
Other comprehensive income, net of tax: | |||
Foreign exchange translation adjustments | (3.8) | 10.4 | 5.7 |
Defined benefit plan loss | (0.6) | 0 | (0.9) |
Income (loss) from derivative agreements | 13.8 | (21.3) | (17.9) |
Other comprehensive income (loss) | 9.4 | (10.9) | (13.1) |
Comprehensive income | $ 836.9 | $ 775 | $ 602.8 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Current Assets | ||
Cash and cash equivalents | $ 240.6 | $ 183.1 |
Accounts receivable, less allowances of $5.5 and $3.7 | 405.5 | 398.8 |
Inventories | 535.4 | 495.4 |
Other current assets | 51.9 | 35.1 |
Total Current Assets | 1,233.4 | 1,112.4 |
Property, Plant and Equipment, Net | 652.7 | 612.8 |
Equity Investment in Affiliates | 9.1 | 9.1 |
Trade Names and Other Intangibles, Net | 3,494.3 | 3,110.2 |
Goodwill | 2,274.5 | 2,229.6 |
Other Assets | 332.5 | 340.4 |
Total Assets | 7,996.5 | 7,414.5 |
Current Liabilities | ||
Short-term borrowings | 252.8 | 351.4 |
Current portion of long-term debt | 699.4 | 0 |
Accounts payable and accrued expenses | 1,119.7 | 1,024.5 |
Income taxes payable | 3.3 | 12.7 |
Total Current Liabilities | 2,075.2 | 1,388.6 |
Long-term Debt | 1,610.7 | 1,812.5 |
Deferred Income Taxes | 745.1 | 707.3 |
Deferred and Other Long-term Liabilities | 298.3 | 367.7 |
Business Acquisition Liabilities | 34 | 118 |
Total Liabilities | 4,763.3 | 4,394.1 |
Commitments and Contingencies | ||
Stockholders' Equity | ||
Preferred Stock, $1.00 par value, Authorized 2,500,000 shares; none issued | 0 | 0 |
Common Stock, $1.00 par value, Authorized 600,000,000 shares; 292,855,100 shares issued as of December 31, 2021 and 2020 | 292.8 | 292.8 |
Additional paid-in capital | 310.3 | 274.4 |
Retained earnings | 5,366 | 4,786 |
Accumulated other comprehensive loss | (68.2) | (77.6) |
Common stock in treasury, at cost: 50,309,124 shares as of December 31, 2021 and 47,494,982 shares as of December 31, 2020 | (2,667.7) | (2,255.2) |
Total Stockholders' Equity | 3,233.2 | 3,020.4 |
Total Liabilities and Stockholders’ Equity | $ 7,996.5 | $ 7,414.5 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Statement Of Financial Position [Abstract] | ||
Accounts receivable, allowances | $ 5.5 | $ 3.7 |
Preferred Stock, par value | $ 1 | $ 1 |
Preferred Stock, Authorized | 2,500,000 | 2,500,000 |
Preferred Stock, issued | 0 | 0 |
Common Stock, par value | $ 1 | $ 1 |
Common Stock, Authorized | 600,000,000 | 600,000,000 |
Common Stock, shares issued | 292,855,100 | 292,855,100 |
Common stock in treasury, shares | 50,309,124 | 47,494,982 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Cash Flow From Operating Activities | |||
Net Income | $ 827.5 | $ 785.9 | $ 615.9 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation expense | 68.4 | 66.2 | 63.8 |
Amortization expense | 150.7 | 123.5 | 112.6 |
Change in fair value of business acquisition liabilities | (98) | (93.7) | 1.3 |
Deferred income taxes | 20.3 | 25.7 | 5.6 |
Equity in net earnings of affiliates | (9.4) | (6.7) | (6.6) |
Distributions from unconsolidated affiliates | 9.4 | 7.4 | 5.3 |
Non-cash compensation expense | 23.7 | 21.5 | 20.8 |
Asset impairment charge and other asset write-offs | 14.9 | 1.9 | 13.8 |
Gain on sale of assets | 0 | (3) | 0 |
Other | 3.6 | 2.3 | 0.1 |
Change in assets and liabilities: | |||
Accounts receivable | 2.4 | (13.4) | (9.2) |
Inventories | (29.1) | (61.9) | (33.8) |
Other current assets | (6.1) | (10.2) | 4.9 |
Accounts payable and accrued expenses | 47.5 | 168 | 72.8 |
Income taxes payable | (16) | 12.2 | 3.4 |
Other operating assets and liabilities, net | (16) | (35.4) | (6.2) |
Net Cash Provided By Operating Activities | 993.8 | 990.3 | 864.5 |
Cash Flow From Investing Activities | |||
Additions to property, plant and equipment | (118.8) | (98.9) | (73.7) |
Proceeds from sale of assets | 0 | 7 | 0 |
Acquisitions | (556) | (512.7) | (475) |
Other | (7.2) | (3.5) | (4.8) |
Net Cash Used In Investing Activities | (682) | (608.1) | (553.5) |
Cash Flow From Financing Activities | |||
Long-term debt borrowings | 799.2 | 0 | 300 |
Long-term debt (repayments) | (300) | 0 | (600) |
Short-term debt (repayments), net of borrowings | (98.5) | 99 | 251 |
Proceeds from stock options exercised | 98.7 | 93 | 52.8 |
Payment of cash dividends | (247.5) | (237.3) | (224.1) |
Purchase of treasury stock | (500) | (300) | (250) |
Payment of business acquisition liabilities | 0 | (14.5) | 0 |
Deferred financing and other | (4) | (0.3) | (2.6) |
Net Cash Used In Financing Activities | (252.1) | (360.1) | (472.9) |
Effect of exchange rate changes on cash and cash equivalents | (2.2) | 5.3 | 0.9 |
Net Change In Cash and Cash Equivalents | 57.5 | 27.4 | (161) |
Cash and Cash Equivalents at Beginning of Period | 183.1 | 155.7 | 316.7 |
Cash and Cash Equivalents at End of Period | 240.6 | 183.1 | 155.7 |
Cash paid during the year for: | |||
Interest (net of amounts capitalized) | 51.8 | 58.8 | 70.6 |
Income taxes | 202.8 | 162.1 | 134.8 |
Supplemental disclosure of non-cash investing activities: | |||
Property, plant and equipment expenditures included in Accounts Payable | $ 10.7 | $ 20.1 | $ 10.4 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Millions, $ in Millions | Total | Common Stock | Treasury Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Income (Loss) |
Beginning Balance at Dec. 31, 2018 | $ 2,453.8 | $ 292.8 | $ (1,898.8) | $ 280.8 | $ 3,832.6 | $ (53.6) |
Beginning Balance (in shares) at Dec. 31, 2018 | 292.8 | (46) | ||||
Adoption of new accounting pronouncements | 13 | $ 0 | $ 0 | 0 | 13 | 0 |
Net Income | 615.9 | 0 | 0 | 0 | 615.9 | 0 |
Other comprehensive (loss) income | (13.1) | 0 | 0 | 0 | 0 | (13.1) |
Cash dividends | (224.1) | 0 | 0 | 0 | (224.1) | 0 |
Stock purchases | (250) | $ 0 | $ (250) | 0 | 0 | 0 |
Stock purchases (in shares) | 0 | (3.6) | ||||
Stock based compensation expense and stock option plan transactions | 72.3 | $ 0 | $ 57.6 | 14.7 | 0 | 0 |
Stock based compensation expense and stock option plan transactions (in shares) | 0 | 2.2 | ||||
Ending Balance at Dec. 31, 2019 | 2,667.8 | $ 292.8 | $ (2,091.2) | 295.5 | 4,237.4 | (66.7) |
Ending Balance (in shares) at Dec. 31, 2019 | 292.8 | (47.4) | ||||
Net Income | 785.9 | $ 0 | $ 0 | 0 | 785.9 | 0 |
Other comprehensive (loss) income | (10.9) | 0 | 0 | 0 | 0 | (10.9) |
Cash dividends | (237.3) | 0 | 0 | 0 | (237.3) | 0 |
Stock purchases | (300) | $ 0 | $ (270) | (30) | 0 | 0 |
Stock purchases (in shares) | 0 | (3.1) | ||||
Stock based compensation expense and stock option plan transactions | 114.9 | $ 0 | $ 106 | 8.9 | 0 | 0 |
Stock based compensation expense and stock option plan transactions (in shares) | 0 | 3.1 | ||||
Ending Balance at Dec. 31, 2020 | 3,020.4 | $ 292.8 | $ (2,255.2) | 274.4 | 4,786 | (77.6) |
Ending Balance (in shares) at Dec. 31, 2020 | 292.8 | (47.4) | ||||
Net Income | 827.5 | $ 0 | $ 0 | 0 | 827.5 | 0 |
Other comprehensive (loss) income | 9.4 | 0 | 0 | 0 | 0 | 9.4 |
Cash dividends | (247.5) | 0 | 0 | 0 | (247.5) | 0 |
Stock purchases | (500) | $ 0 | $ (510) | 10 | 0 | 0 |
Stock purchases (in shares) | 0 | (5.7) | ||||
Stock based compensation expense and stock option plan transactions | 123.4 | $ 0 | $ 97.5 | 25.9 | 0 | 0 |
Stock based compensation expense and stock option plan transactions (in shares) | 0 | 2.8 | ||||
Ending Balance at Dec. 31, 2021 | $ 3,233.2 | $ 292.8 | $ (2,667.7) | $ 310.3 | $ 5,366 | $ (68.2) |
Ending Balance (in shares) at Dec. 31, 2021 | 292.8 | (50.3) |
Significant Accounting Policies
Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | 1. Significant Accounting Policies Business The Company, founded in 1846, develops, manufactures and markets a broad range of household, personal care and specialty products focused on animal productivity, chemicals and cleaners. The Company sells its consumer products under a variety of brands through a broad distribution platform that includes supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar, pet and other specialty stores and websites and other e-commerce channels, all of which sell the products to consumers. The Company also sells specialty products to industrial customers, livestock producers and through distributors. Basis of Presentation The accompanying Consolidated Financial Statements are presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and include the accounts of the Company and its majority‑owned subsidiaries. For equity investments in which the Company does not control or have the ability to exert significant influence over the investee, which generally is when the Company has less than a 20% ownership interest, the investments are accounted for under the cost method. In circumstances where the Company has greater than a 20% ownership interest and has the ability to exercise significant influence over, but does not control, the investee, the investment is accounted for under the equity method. As a result, the Company accounts for its 50% interest in its Armand Products Company (“Armand”) joint venture and its 50% interest in The ArmaKleen Company (“ArmaKleen”) joint venture under the equity method. Armand and ArmaKleen are specialty chemical businesses. The Company’s equity in earnings of Armand and ArmaKleen are included in the Corporate segment, as described in Note 16. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent gains and losses at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Management makes estimates regarding inventory valuation, promotional and sales returns reserves, the carrying amount of goodwill and other intangible assets, the realization of deferred tax assets, tax reserves, business acquisition liabilities, liabilities related to other postretirement benefit obligations and other matters that affect the reported amounts and other disclosures in the financial statements. These estimates are based on judgment and available information. Actual results could differ materially from those estimates, and it is possible that changes in such estimates could occur in the near term. Revenue Recognition Revenue is recognized when control of a promised good is transferred to a customer in an amount that reflects the consideration that the Company expects to be entitled to in exchange for that good. This usually occurs when finished goods are delivered to the Company’s customers or when finished goods are picked up by a customer or a customer’s carrier. a. Nature of Goods and Services The Company primarily ships finished goods to its customers and operates in three segments: Consumer Domestic, Consumer International and Specialty Products Division (“SPD”). The segments are based on differences in the nature of products and organizational and ownership structures. The Consumer Domestic and Consumer International segments market a variety of personal care and household products and over-the-counter products, including but not limited to baking soda, cat litter, laundry detergent, condoms, stain removers, hair removal, gummy dietary supplements, dry shampoo, water flossers and showerheads. The SPD segment focuses on sales to businesses and participates in three product areas: Animal and Food Production, Specialty Chemicals and Specialty Cleaners. The Company’s products are distinct and separately identifiable on customer contracts or invoices, with each product sale representing a separate performance obligation. The Company sells consumer products under a variety of brands through a broad distribution platform that includes supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar, pet and other specialty stores and websites and other e-commerce channels, all of which sell its products to consumers. The Company sells its specialty products to industrial customers, livestock producers and through distributors. Refer to Note 17 for disaggregated revenue information with respect to each of the Company’s segments. b. When Performance Obligations are Satisfied For performance obligations related to the shipping and invoicing of products, control transfers at the point in time upon which finished goods are delivered to the Company’s customers or when finished goods are picked up by a customer or a customer’s carrier. Once a product has been delivered or picked up by the customer, the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset. The Company considers control to have transferred upon delivery or customer receipt because the Company has an enforceable right to payment at that time, the customer has legal title to the asset, the Company has transferred physical possession of the asset, and the customer has significant risk and rewards of ownership of the asset. c. Variable Consideration The Company conducts extensive promotional activities, primarily through the use of off-list discounts, slotting, coupons, cooperative advertising, periodic price reduction arrangements, and end-aisle and other in-store displays. The costs of such activities are netted against sales and are recorded when the related sale takes place. The reserves for sales returns and consumer and trade promotion liabilities are established based on the Company’s best estimate of the amounts necessary to settle future and existing obligations for products sold as of the balance sheet date. The Company uses historical trend experience and coupon redemption inputs in arriving at coupon reserve requirements, and uses forecasted appropriations, customer and sales organization inputs, and historical trend analysis in determining the reserves for other promotional activities and sales returns. d. Practical Expedients The Company expenses incremental direct costs of obtaining a contract (broker commissions) when the related sale takes place. These costs are recorded in SG&A expenses in the accompanying consolidated statements of income. The Company accounts for shipping and handling costs as fulfillment activities which are therefore recognized upon shipment of the goods. The Company has applied the portfolio approach to all open contracts as they have similar characteristics and can reasonably expect that the effects on the financial statements of applying this new guidance to the portfolio of contracts would not differ materially from applying this guidance to the individual contracts within the portfolio. The Company excludes from its revenue any amounts collected from customers for sales (and similar) taxes. Sales of Accounts Receivable The Company entered into a factoring agreement with a financial institution to sell certain customer receivables at discounted rates in 2015. Transactions under this agreement are accounted for as sales of accounts receivable and are removed from the Consolidated Balance Sheet at the time of the sales transaction. As the customers associated with the Company’s factoring program have been consistent in recent years, the sales performance by customer has driven the amount factored each year. The Company factored an incremental $21.2, $21.1, and $26.0 during the years ended December 31, 2021, 2020 and 2019, respectively. Cost of Sales, Marketing and Selling, General and Administrative Expenses Cost of sales include costs related to the manufacture of the Company’s products, including raw material, inbound freight, direct labor (including employee compensation benefits) and indirect plant costs such as plant supervision, receiving, inspection, maintenance labor and materials, depreciation, taxes and insurance, purchasing, production planning, operations management, logistics, freight to customers, warehousing costs, internal transfer freight costs and plant impairment charges. Marketing expenses include costs for advertising (excluding the costs of cooperative advertising programs, which are reflected in net sales), costs for coupon insertion (mainly the cost of printing and distribution), consumer promotion costs (such as on-shelf advertisements and floor ads), public relations, package design expense and market research costs. Selling, general and administrative expenses (“SG&A”) expenses include, among others, costs related to functions such as sales, corporate management, research and development, marketing administration, information technology and legal. Such costs include salary compensation related costs (such as benefits, incentive compensation and profit sharing), stock option costs, depreciation, travel and entertainment related expenses, professional and other consulting fees and amortization of intangible assets. Foreign Currency Translation Unrealized gains and losses related to currency translation are recorded in Accumulated Other Comprehensive Income (Loss). Gains and losses on foreign currency transactions are recorded in the Consolidated Statements of Income. Cash Equivalents Cash equivalents consist of highly liquid short-term investments and term bank deposits, which mature within three months of their original maturity date. Inventories Inventories are valued at the lower of cost or market (net realizable value, which reflects any costs to sell or dispose). The Company identifies any slow moving, obsolete or excess inventory to determine whether an adjustment is required to establish a new carrying value. The determination of whether inventory items are slow moving, obsolete or in excess of needs requires estimates and assumptions about the future demand for the Company’s products, technological changes, and new product introductions. Estimates as to the future demand used in the valuation of inventory involve judgments regarding the ongoing success of the Company’s products. The Company evaluates its inventory levels and expected usage on a periodic basis and records adjustments as required. Adjustments to reflect inventory at net realizable value were $36.2 at December 31, 2021, and $17.0 at December 31, 2020. Property, Plant and Equipment Property, Plant and Equipment (“PP&E”) are stated at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets. Estimated useful lives for building and improvements, machinery and equipment, and office equipment range from 9-40, 3-20 and 3-10 years, respectively. Routine repairs and maintenance are expensed when incurred. Leasehold improvements are depreciated over a period no longer than the respective lease term, except where a lease renewal has been determined to be reasonably assured and failure to renew the lease results in a significant penalty to the Company. PP&E is reviewed annually and whenever events or changes in circumstances indicate that possible impairment exists. The Company’s impairment review is based on an undiscounted cash flow analysis at the lowest level at which cash flows of the long-lived assets are largely independent of other groups of Company assets and liabilities. The analysis requires management judgment with respect to changes in technology, the continued success of product lines, and future volume, revenue and expense growth rates. The Company conducts annual reviews to identify idle and underutilized equipment, and reviews business plans for possible impairment. Impairment occurs when the carrying value of the asset exceeds the future undiscounted cash flows. When an impairment is indicated, the estimated future cash flows are then discounted to determine the estimated fair value of the asset and an impairment charge is recorded for the difference between the carrying value and the net present value of estimated future cash flows. Software The Company capitalizes certain costs of developing computer software. Amortization is recorded using the straight‑line method over the estimated useful life of the software, which is estimated to be no longer than 10 years. Fair Value of Financial Instruments Certain financial instruments are required to be recorded at fair value. The estimated fair values of such financial instruments (including investment securities and other derivatives) have been determined using market information and valuation methodologies. Changes in assumptions or estimation methods could affect the fair value estimates. Other financial instruments, including cash equivalents and short-term debt, are recorded at cost, which approximates fair value. Additional information regarding the Company’s risk management activities, including derivative instruments and hedging activities, are separately disclosed. See Notes 2 and 3. Goodwill and Other Intangible Assets Carrying values of goodwill and indefinite-lived trade names are reviewed periodically for possible impairment. The Company’s impairment analysis is based on a discounted cash flow approach that requires significant judgment with respect to unit volume, revenue and expense growth rates, and the selection of an appropriate discount rate and royalty rate. Management uses estimates based on expected trends in making these assumptions. With respect to goodwill, impairment occurs when the carrying value of the reporting unit exceeds the discounted present value of cash flows for that reporting unit. For trade names and other intangible assets, an impairment charge is recorded for the difference between the carrying value and the net present value of estimated future cash flows, which represents the estimated fair value of the asset. Judgment is required in assessing whether assets may have become impaired between annual valuations. Indicators such as unexpected adverse economic factors, unanticipated technological change, distribution losses, or competitive activities and acts by governments and courts may indicate that an asset has become impaired. Intangible assets with finite lives are amortized over their estimated useful lives, which range from 3-20 years, using the straight-line method, and reviewed for impairment when changes in market circumstances occur. It is possible that the Company’s conclusions regarding impairment or recoverability of goodwill or other intangible assets could change in future periods if, for example, (i) the businesses or brands do not perform as projected, (ii) overall economic conditions in future years vary from current assumptions (including changes in discount rates), (iii) business conditions or strategies change from current assumptions, (iv) investors require higher rates of return on equity investments in the marketplace or (v) enterprise values of comparable publicly traded companies, or actual sales transactions of comparable companies, were to decline, resulting in lower multiples of revenues and EBITDA. Research and Development The Company incurred research and development expenses in the amount of $105.2, $102.6 and $93.6 in 2021, 2020 and 2019, respectively. These expenses are included in SG&A expenses and are expensed as incurred. Earnings Per Share (“EPS”) Basic EPS is calculated based on income available to holders of the Company’s common stock (“Common Stock”) and the weighted-average number of shares outstanding during the reported period. Diluted EPS includes additional dilution from potential Common Stock issuable pursuant to the exercise of outstanding stock options. The following table sets forth a reconciliation of the weighted-average number of shares of Common Stock outstanding to the weighted-average number of shares outstanding on a diluted basis: 2021 2020 2019 Weighted average common shares outstanding - basic 244.9 246.8 246.2 Dilutive effect of stock options 4.7 5.4 5.9 Weighted average common shares outstanding - diluted 249.6 252.2 252.1 Antidilutive stock options outstanding 1.6 1.5 1.5 Employee and Director Stock Based Compensation The fair value of share-based compensation is determined at the grant date and the related expense is recognized over the required employee service period in which the share-based compensation vests. The following table presents the pre-tax expense associated with the fair value of unvested stock options and restricted stock awards included in SG&A expenses and in cost of sales: For the Year Ended December 31, 2021 2020 2019 Cost of sales $ 3.3 $ 3.6 $ 2.8 Selling, general and administrative expenses 22.3 21.0 19.6 Total $ 25.6 $ 24.6 $ 22.4 Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized to reflect the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the differences are expected to be recovered or settled. Management provides a valuation allowance against deferred tax assets for amounts which are not considered “more likely than not” to be realized. The Company records liabilities for potential assessments in various tax jurisdictions in accordance with GAAP. The liabilities relate to tax return positions that, although supportable by the Company, may be challenged by the tax authorities and do not meet the minimum recognition threshold required under applicable accounting guidance for the related tax benefit to be recognized in the income statement. The Company adjusts this liability as a result of changes in tax legislation, interpretations of laws by courts, rulings by tax authorities, changes in estimates and the expiration of the statute of limitations. Many of the judgments involved in adjusting the liability involve assumptions and estimates that are highly uncertain and subject to change. In this regard, settlement of any issue with, or an adverse determination in litigation against, a taxing authority could require the use of cash and result in an increase in the Company’s annual tax rate. Conversely, favorable resolution of an issue with a taxing authority would be recognized as a reduction to the Company’s annual tax rate. Recently Adopted Accounting Pronouncements In March 2020, the FASB issued new accounting guidance intended to provide temporary optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (“LIBOR”) and other interbank offered rates to alternative reference rates. This guidance was effective beginning on March 12, 2020, and the Company may apply the amendments prospectively to contract modifications made or relationships entered into or evaluated through December 31, 2022. The adoption of this guidance did not have an impact on the Company’s consolidated financial position, results of operations or cash flows in the current period. The Company will continue to evaluate the impacts of this guidance on future contract modifications through December 31, 2022. In February 2016 and July 2018, the FASB issued new lease accounting guidance, requiring lessees to recognize right-of-use lease assets and lease liabilities on the balance sheet for those leases previously classified as operating leases, with a term greater than a year. The new guidance also expands the required quantitative and qualitative disclosures surrounding leases. The guidance was effective for annual and interim periods beginning after December 15, 2018, and allowed companies to apply the requirements retrospectively, either to all prior periods presented or through a cumulative adjustment in the year of adoption. The Company adopted the new standard on January 1, 2019 using the optional transition method of adoption which permits the entity to continue presenting all periods prior to January 1, 2019 under the previous lease accounting guidance. The Company has implemented the appropriate internal controls and applications to monitor and record historical and future lease arrangements and required disclosures. For all existing operating leases as of December 31, 2018, the Company recorded Right of Use Assets of approximately $55.0 and corresponding lease liabilities of approximately $57.0 with an offset to Deferred and Other Long-term Liabilities of approximately $2.0 to eliminate deferred rent on the consolidated balance sheet. In addition, based on the transition guidance surrounding failed sale-and-leaseback transactions, the Company re-evaluated the lease for its corporate headquarters in Ewing, New Jersey. This lease was previously considered a failed sale-and-leaseback transaction under Accounting Standards Codification (“ASC”) 840 because of continuing involvement. The re-evaluation resulted in a change in classification from a finance transaction to an operating lease. The corporate headquarters building, which had a net book value of approximately $35.0 recorded in Property, Plant and Equipment as of December 31, 2018, was derecognized on January 1, 2019 and a Right of Use Asset of approximately $52.0 was recorded with an offset to Deferred Income Taxes of $4.0 and Retained Earnings of $13.0. The Lease Liability pertaining to this asset of $52.0 remained unchanged. In total, at the adoption of the new accounting guidance there were Right of Use Assets of approximately $107.0 and a corresponding Lease Liabilities of $109.0. This did not include an existing cease-use liability of approximately $7.0 pertaining to one of the Company’s previous corporate offices that remained unchanged as a result of the transition. Refer to Note 8 for the Company’s lease disclosures. The effects of the recently adopted lease accounting standard to the Company’s consolidated balance sheet as of January 1, 2019 is as follows: Balance at New Lease Balance at December 31, Standard January 1, 2018 Adjustment 2019 Property, plant and equipment, net $ 598.2 $ (35.2 ) $ 563.0 Other assets 117.4 107.5 224.9 Accounts payable and accrued expenses 725.1 13.6 738.7 Deferred and other long-term liabilities 180.9 41.3 222.2 Deferred income taxes 576.4 4.4 580.8 Retained earnings 3,832.6 13.0 3,845.6 The adoption of the new lease accounting standard did not have a material impact on the Company’s results of operations or cash flows. Recent Accounting Pronouncements Not Yet Adopted There have been no other accounting pronouncements issued but not yet adopted by the Company which are expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows. |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 2. Fair Value Measurements Fair Value Hierarchy Accounting guidance on fair value measurements and disclosures establishes a hierarchy that prioritizes the inputs used to measure fair value (generally, assumptions that market participants would use in pricing an asset or liability) based on the quality and reliability of the information provided by the inputs, as follows: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. Fair Values of Other Financial Instruments The following table presents the carrying amounts and estimated fair values of the Company’s other financial instruments at December 31, 2021 and December 31, 2020: December 31, 2021 December 31, 2020 Input Carrying Fair Carrying Fair Level Amount Value Amount Value Financial Assets: Cash equivalents Level 1 $ 17.1 $ 17.1 $ 73.7 $ 73.7 Financial Liabilities: Short-term borrowings Level 2 252.8 252.8 351.4 351.4 Term loan due May 1, 2022 Level 2 0.0 0.0 300.0 300.0 2.45% Senior notes due August 1, 2022 Level 2 300.0 302.9 299.9 310.1 2.875% Senior notes due October 1, 2022 Level 2 399.9 406.4 399.9 416.6 Term loan due December 22, 2024 Level 2 400.0 400.0 0.0 0.0 3.15% Senior notes due August 1, 2027 Level 2 424.7 450.1 424.7 472.4 2.3% Senior notes due December 15, 2031 Level 2 399.2 403.5 0.0 0.0 3.95% Senior notes due August 1, 2047 Level 2 397.5 471.6 397.4 502.2 Interest Rate Swap Lock Agreement liability Level 2 41.6 41.6 57.0 57.0 Business Acquisition Liabilities Level 3 34.0 34.0 118.0 118.0 The Company recognizes transfers between input levels as of the actual date of the event. There were no transfers between input levels during the twelve months ended December 31, 2021. The following methods and assumptions were used to estimate the fair value of each class of financial instruments reflected in the Consolidated Balance Sheets: Cash Equivalents: Cash equivalents consist of highly liquid short-term investments and term bank deposits, which mature within three months. The estimated fair value of the Company’s cash equivalents approximates their carrying value. Short-Term Borrowings: The carrying amounts of the Company’s unsecured lines of credit and commercial paper issuances approximates fair value because of their short maturities and variable interest rates. Senior Notes: The Company determines the fair value of its senior notes based on their quoted market value or broker quotes, when possible. In the absence of observable market quotes, the notes are valued using non-binding market consensus prices that the Company seeks to corroborate with observable market data. Interest Rate Swap Lock Agreement: The Company entered into interest rate swap lock agreements (“Interest Rate Swap Lock Agreements”) which are used to hedge the risk of changes in the interest payments attributable to changes in the benchmark U.S. Dollar London Interbank Offered Rate (“LIBOR”) interest rate associated with anticipated issuances of debt in 2022. These interest rate swap lock agreements have been designated as cash flow hedges and have a notional amount of $300.0. The liability decreased by $15.4 during the year ended December 31, 2021 primarily due to higher current and projected interest rates with the offset in Accumulated Other Comprehensive Loss and Deferred Taxes. The liability was reclassified to Accounts Payable and Accrued Expenses during the third quarter of 2021 . Business Acquisition Liabilities: The business acquisition liabilities represent the estimated fair value of additional future contingent consideration payable for acquisitions of businesses that included contingent consideration clauses. The fair value of business acquisition liabilities is evaluated on an ongoing basis and is based on management estimates and entity-specific assumptions which are considered Level 3 inputs. As of December 31, 2021, the Company had a business acquisition liability of $20.0 in connection with the Zicam Acquisition and a $14.0 business acquisition liability in connection with the TheraBreath Acquisition (b oth of which are defined in Note 6). Any amount that may be due for the Zicam business acquisition liability is payable five years from the closing date. Any amount that may be due for the TheraBreath business acquisition liability is payable in installments between two and four years from the closing. As of December 31, 2020, the Company had a business acquisition liability related to the Flawless Acquisition of $98.0 and a $20.0 liability in connection with the Zicam acquisition which is payable five years from the closing date. The initial fair value of the Flawless business acquisition liability was $182.0. That amount was established based on initial projections in the purchase price allocation. Since the initial fair value was established, the Company has recorded a reduction in fair value of the entire $ 182.0 business acquisition liability of which $ 98.0 was recorded in the twelve months ended December 31, 2021, based on the revised valuation due to updated sales forecasts. The reduction in fair value was recorded as a reduction in SG&A expense within the Consumer Domestic and Consumer International segments. At December 31, 2021 , which was the end of the earn out period, the business acquisition liability value was $0.0 . See Note 15 for further details. The fair value measurement of the business acquisition liabilities is determined using Level 3 inputs. The fair value is determined using the present value of the weighted probabilities of the possible payments due to randomly changing revenue growth. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the fair value of the business acquisition liabilities. Changes in the fair value of the business acquisition liabilities are recorded in general and administrative expenses in the accompanying consolidated statements of operations. Other : The carrying amounts of accounts receivable, and accounts payable and accrued expenses, approximated estimated fair values as of December 31, 2021 and 2020. |
Derivative Instruments and Risk
Derivative Instruments and Risk Management | 12 Months Ended |
Dec. 31, 2021 | |
Derivative Instruments And Hedging Activities Disclosure [Abstract] | |
Derivative Instruments and Risk Management | 3. Derivative Instruments and Risk Management Changes in interest rates, foreign exchange rates, the price of the Common Stock and commodity prices expose the Company to market risk. The Company manages these risks by the use of derivative instruments, such as cash flow and fair value hedges, diesel and commodity hedge contracts, equity derivatives and foreign exchange forward contracts. The Company does not use derivatives for trading or speculative purposes. The Company formally designates and documents qualifying instruments as hedges of underlying exposures when it enters into derivative arrangements. Changes in the fair value of derivatives designated as hedges and qualifying for hedge accounting are recorded in other comprehensive income and reclassified into earnings during the period in which the hedged exposure affects earnings. The Company reviews the effectiveness of its hedging instruments on a quarterly basis. If the Company determines that a derivative instrument is no longer effective in offsetting changes in fair values or cash flows, it recognizes the hedge ineffectiveness in current period earnings and discontinues hedge accounting with respect to the derivative instrument. Changes in the fair value of derivatives not designated as hedges or those not qualifying for hedge accounting are recognized in current period earnings. Upon termination of cash flow hedges, the Company reclassifies gains and losses from accumulated other comprehensive income based on the timing of the underlying cash flows, unless the termination results from the failure of the intended transaction to occur in the expected timeframe. Such untimely transactions require immediate recognition in earnings of gains and losses previously recorded in other comprehensive income. During 2021 and 2020, the Company used derivative instruments to mitigate risk, some of which were designated as hedging instruments. The tables following the discussion of the derivative instruments below summarize the fair value of the Company’s derivative instruments and the effect of derivative instruments on the Company’s consolidated Statement of Operations and on other comprehensive income. Derivatives Designated as Hedging Instruments Diesel Fuel Hedges The Company uses independent freight carriers to deliver its products. These carriers currently charge the Company a basic rate per mile for diesel fuel price increases. The Company has entered into hedge agreements with counterparties to mitigate the volatility of diesel fuel prices, and not to speculate in the future price of diesel fuel. Under the hedge agreements, the Company agreed to pay a fixed price per gallon of diesel fuel determined at the time the agreements were executed and to receive a floating rate payment that is determined on a monthly basis based on the average price of the Department of Energy’s Diesel Fuel Index during the applicable month and is designed to offset any increase or decrease in fuel costs that the Company pays to it common carriers. The agreements covered approximately 75% of the Company’s 2021 diesel fuel requirements. Foreign Currency The Company is subject to exposure from fluctuations in foreign currency exchange rates, primarily U.S. Dollar/Euro, U.S. Dollar/ Pound, U.S. Dollar/Canadian Dollar, U.S. Dollar/Mexican Peso, and U.S. Dollar/Australian Dollar. The Company enters into forward exchange contracts to reduce the impact of foreign exchange rate fluctuations related to anticipated but not yet committed sales or purchases denominated in U.S. Dollar, Canadian Dollar, Pound, Euro, Mexican Peso, Chinese Yuan, and Australian Dollar. The Company entered into forward exchange contracts to hedge itself from the risk that, due to fluctuations in currency exchange rates, it would be adversely affected by net cash outflows. The face value of the unexpired contracts as of December 31, 2021 totaled $222.2 in U.S. Dollars, of which Interest Rate Swap Lock Agreement The Company entered into interest rate swap lock agreements to hedge the risk of changes in the interest payments attributable to changes in the benchmark LIBOR interest rate associated with anticipated issuances of debt These interest rate swap lock agreements have been designated as cash flow hedges and have a notional amount of $300.0. Commodity Hedges The Company is subject to exposure due to changes in prices of commodities used in production. To limit the effects of fluctuations in the future market price paid and related volatility in cash flows, the Company enters into commodity forward swap contracts. These hedges are designated as cash flow hedges for accounting purposes and, therefore, changes in the fair value of the contracts are recorded in Accumulated Other Comprehensive Income (Loss) and reclassified to earnings when the hedged transaction affected earnings. The fair value of these commodity hedge agreements is reflected in the Consolidated Balance Sheet within Other Current Assets and Accounts Payable and Accrued Expenses. Derivatives not Designated as Hedging Instruments Equity Derivatives The Company has entered into equity derivative contracts covering the Common Stock in order to minimize its liability under its Executive Deferred Compensation Plan resulting from changes in the quoted fair values of the Common Stock to participants who have investments under the Plan in a notional Common Stock fund. The contracts are settled in cash. Since the equity derivatives contracts do not qualify for hedge accounting, The notional amount of a derivative instrument is the nominal or face amount used to calculate payments made on that instrument. Notional amounts are presented in the following table: Notional Notional Amount Amount December 31, 2021 December 31, 2020 Derivatives designated as hedging instruments Foreign exchange contracts $ 216.3 $ 252.7 Interest rate swap lock $ 300.0 $ 300.0 Diesel fuel contracts 0.0 gallons 6.7 gallons Commodities contracts 72.1 pounds 84.0 pounds Derivatives not designated as hedging instruments Foreign exchange contracts $ 5.9 $ 8.0 Equity derivatives $ 28.9 $ 23.3 Excluding the interest rate swap lock disclosed in Note 2, the fair values and amount of gain (loss) recognized in income and other comprehensive income associated with the derivative instruments disclosed above do not have a material impact on the Company’s consolidated financial statements. |
Inventories
Inventories | 12 Months Ended |
Dec. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Inventories | 4. Inventories Inventories consist of the following: December 31, December 31, 2021 2020 Raw materials and supplies $ 116.2 $ 112.9 Work in process 40.0 33.0 Finished goods 379.2 349.5 Total $ 535.4 $ 495.4 |
Property, Plant and Equipment,
Property, Plant and Equipment, Net ("PP&E") | 12 Months Ended |
Dec. 31, 2021 | |
Property Plant And Equipment [Abstract] | |
Property, Plant and Equipment, Net ("PP&E") | 5. Property, Plant and Equipment, Net (“PP&E”) PP&E consist of the following: December 31, December 31, 2021 2020 Land $ 28.3 $ 28.3 Buildings and improvements 290.8 265.3 Machinery and equipment 828.9 793.4 Software 107.8 103.0 Office equipment and other assets 92.7 85.1 Construction in progress 104.3 86.8 Gross PP&E 1,452.8 1,361.9 Less accumulated depreciation and amortization 800.1 749.1 Net PP&E $ 652.7 $ 612.8 For the Year Ended December 31, 2021 2020 2019 Depreciation expense on PP&E $ 68.4 $ 66.2 $ 63.8 |
Acquisitions
Acquisitions | 12 Months Ended |
Dec. 31, 2021 | |
Business Combinations [Abstract] | |
Acquisitions | 6. Acquisitions On December 24, 2021, the Company acquired all of the outstanding equity of Dr. Harold Katz, LLC and HK-IP International, Inc. , the owners of the THERABREATH® brand of oral care products business (the “TheraBreath Acquisition”). The Company paid $556.0, net of cash acquired, at closing and deferred an additional cash payment of $14.0 related to certain indemnity obligations provided by the seller. The additional amount, to the extent not used in satisfaction of such indemnity obligations, is payable in installments between two and four years from the closing. T HERABREATH ’s annual net sales for the year ended December 31, 2021 were approximately $ 100 . The acquisition was financed by the proceeds from a $ 400.0 three-year term loan and the Company’s underwritten public offering of $ 400.0 aggregate principal Senior Notes due on December 15, 2031 (as defined in Note 10) completed on December 10, 2021. The T HERABREATH business is managed in the Consumer Domestic and Consumer International segments. The preliminary fair values of the net assets at acquisition are set forth as follows: Accounts receivable $ 11.3 Inventory 12.9 Trade name (indefinite lived) 487.0 Other intangible assets 30.1 Goodwill 43.7 Accounts payable and accrued expenses (15.0 ) Business acquisition liabilities - long-term (14.0 ) Cash purchase price (net of cash acquired) $ 556.0 The trade names and other intangible assets were valued using a discounted cash flow model. The life of the amortizable intangible assets recognized from the TheraBreath Acquisition have a useful life which ranges from 10 - 20 years. The goodwill is a result of expected synergies from combined operations of the acquired business and the Company. Pro forma results are not presented because the impact of the acquisition is not material to the Company’s consolidated financial results. The goodwill and other intangible assets associated with the TheraBreath Acquisition are deductible for U.S. tax purposes. On December 1, 2020, the Company acquired all of the outstanding equity of Consumer Health Holdco LLC, the owner of the ZICAM ® and any amount that may be due for the business acquisition liability The fair values of the net assets acquired are set forth as follows: Inventory and other working capital $ 40.2 Property, plant and equipment 0.5 Trade name 367.8 Other intangible assets 93.8 Goodwill 152.2 Current liabilities (13.1 ) Deferred income taxes (108.0 ) Long-term liabilities (20.7 ) Cash purchase price (net of cash acquired) $ 512.7 The trade names and other intangible assets were valued using a discounted cash flow model. All of the intangible assets recognized from the Zicam Acquisition have a useful life which ranges from 10 - 20 years. The goodwill is a result of expected synergies from combined operations of the acquired business and the Company. Pro forma results are not presented because the impact of the acquisition is not material to the Company’s consolidated financial results. The goodwill and other intangible assets associated with the Zicam Acquisition are not deductible for U.S. tax purposes. On May 1, 2019, the Company closed on its previously announced acquisition of the FLAWLESS® business (the “Flawless Acquisition”) from Ideavillage Products Corporation (“Ideavillage”). The Company paid $475.0 at closing and agreed to make an additional business acquisition liability payment based on a trailing twelve-month three-year the principal party to the sales transactions and began recording revenue on a gross basis. The FLAWLESS business is managed in the Consumer Domestic and Consumer International segments and represents an addition to the Company’s specialty haircare portfolio which includes BATISTE® dry shampoo, VIVISCAL hair thinning supplements, and TOPPIK® hair fibers. The fair values of the net assets acquired are set forth as follows: Trade name $ 447.3 Other intangible assets 121.8 Goodwill 87.9 Business acquisition liability (182.0 ) Cash purchase price $ 475.0 As a result of the Company purchasing assets, the goodwill and other intangible assets associated with the Flawless Acquisition are deductible for U.S. tax purposes. The trade names and other intangible assets were valued using a discounted cash flow model. All of the intangible assets recognized from the Flawless Acquisition have a useful life which ranges from 15 - 20 years. The goodwill is a result of expected synergies from combined operations of the acquired business and the Company. Pro forma results are not presented because the impact of the acquisition was not material to the Company’s consolidated financial results. Ideavillage continued to help support the business through a separate transition services agreement which expired on December 31, 2021. |
Goodwill and Other Intangibles,
Goodwill and Other Intangibles, Net | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Goodwill and Other Intangibles, Net | 7. Goodwill and Other Intangibles, Net The following table provides information related to the carrying value of all intangible assets, other than goodwill: December 31, 2021 December 31, 2020 Gross Amortization Gross Carrying Accumulated Period Carrying Accumulated Amount Amortization Net (Years) Amount Amortization Net Amortizable intangible assets: Trade names $ 1,386.7 $ (336.2 ) $ 1,050.5 3-20 $ 1,389.6 $ (269.6 ) $ 1,120.0 Customer Relationships 664.0 (322.4 ) 341.6 15-20 659.5 (291.2 ) 368.3 Patents/Formulas 239.1 (99.4 ) 139.7 4-20 230.5 (85.3 ) 145.2 Total $ 2,289.8 $ (758.0 ) $ 1,531.8 $ 2,279.6 $ (646.1 ) $ 1,633.5 Indefinite lived intangible assets - Carrying value December 31, December 31, 2021 2020 Trade names $ 1,962.5 $ 1,476.7 The increase in indefinite lived intangible assets is due to the TheraBreath Acquisition. Intangible amortization expense amounted to $120.3 for 2021, $99.9 for 2020 and $90.4 for 2019, respectively. The Company estimates that intangible amortization expense will be approximately $117.0 in 2022 and approximately $115.0 to $107.0 annually over the next five years. The Company determined that the carrying value of its trade names as of December 31, 2021 and 2020, was recoverable based upon the forecasted cash flows and profitability of the brands. Fair value for indefinite lived intangible assets was estimated based on a “relief from royalty” or “excess earnings” discounted cash flow method, which contains numerous variables that are subject to change as business conditions change, and therefore could impact fair values in the future. The key assumptions used in determining fair value are sales growth, profitability margins, tax rates, discount rates and royalty rates. The Company determined that the fair value of all indefinite lived intangible assets for each of the years in the three-year period ended December 31, 2021 exceeded their respective carrying values based upon the forecasted cash flows and profitability. The Company’s indefinite lived intangible impairment review is completed in the fourth quarter of each year. In recent years the Company’s TROJAN® business, specifically the condom category, ha s not grown and competition has increased. Social distancing requirements due to the COVID-19 pandemic had further negatively impacted the business. As a result, the TROJAN business had experienced stagnant sales and profits resulting in a reduction in expected future cash flows which eroded a portion of the excess between the fair and carrying value of the tradename. This indefinite-lived intangible asset may be susceptible to impairment risk and a continued decline in fair value could trigger a future impairment charge of the TROJAN tradename. The carrying value of the TROJAN tradename is $ 176.4 and fair value exceeded carrying value by 70 % as of December 31, 202 1 . The k ey assumptions used in the projections from the Company’s October 1, 2021 impairment analysis include discount rates of 7.0 % in the U.S. and 8.5 % internationally, growth assumptions based on recent trends , and an average royalty rate of approximately 10 %. While management can and has implemented strategies to address the risk, including lowering our production costs, investing in new product ideas, and developing new creative advertising, significant changes in operating plans or adverse changes in the future could reduce the underlying cash flows used to estimate fair value. In 2021, TROJAN experienced a recovery in sales and profits as it is benefiting from an easing of COVID-19 social restrictions leading to an increase in sexual activity. The Company expects this trend will continue into next year with the continued adoption of vaccines, the reduction of social distancing restrictions and the benefit of management strategies to improve sales and profitability. The Company’s Passport Food Safety business has experienced sales and profit declines due to decreased demand driven by the COVID-19 pandemic and pressures from new competitive activities resulting from the loss of exclusivity on a key product line. In the fourth quarter of 2021, management’s review of the outlook for the Passport business indicated an assessment of the recoverability of the long-lived assets associated with the business was necessary. That review determined that the estimated future cash flows would not be sufficient to recover the carrying value of the assets resulting in an impairment of the associated tradename and other intangible assets of $11.3. The charge is recorded in selling, general and administrative expenses. The assets have a current remaining net book value of approximately $9.5 and are being amortized over their remaining weighted average life which has been reduced to 7 years. The Company is implementing strategies to address the decline in profitability. However, if unsuccessful, this decline could trigger an additional future impairment charge. During the first quarter of 2020, the Company sold its PERL WEISS® toothpaste brand in Germany with a tradename net book value of $2.7 and corresponding goodwill of $1.3 for cash proceeds of $7.0. The $3.0 gain associated with this transaction was recorded as a reduction of SG&A expense in the Consumer International segment. The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows: Consumer Consumer Specialty Domestic International Products Total Balance at December 31, 2019 $ 1,707.9 $ 235.6 $ 136.0 $ 2,079.5 PERL WEISS divestiture 0.0 (1.3 ) 0.0 (1.3 ) Zicam acquired goodwill 151.4 0.0 0.0 151.4 Balance at December 31, 2020 $ 1,859.3 $ 234.3 $ 136.0 $ 2,229.6 TheraBreath acquired goodwill 39.3 4.4 0.0 43.7 Tax related and other 1.2 0.0 0.0 1.2 Balance at December 31, 2021 $ 1,899.8 $ 238.7 $ 136.0 $ 2,274.5 The result of the Company’s annual goodwill impairment test, performed in the beginning of the second quarter of 2021, determined that the estimated fair value substantially exceeded the carrying values of all reporting units. The determination of fair value contains numerous variables that are subject to change as business conditions change and therefore could impact fair value in the future. The Company has never incurred a goodwill impairment charge. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2021 | |
Leases [Abstract] | |
Leases | 8. Leases The Company leases certain manufacturing facilities, warehouses, office space, railcars and equipment. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. All recorded leases are classified as operating leases and lease expense is recognized on a straight-line basis over the lease term. For leases beginning in 2019, lease components (base rental costs) are accounted for separately from the nonlease components (e.g., common-area maintenance costs). For leases that do not provide an implicit rate, the Company uses its estimated secured incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A summary of the Company’s lease information is as follows: December 31, December 31, Classification 2021 2020 Assets Right of use assets Other Assets $ 159.4 $ 181.6 Liabilities Current lease liabilities Accounts Payable and Accrued Expenses $ 24.4 $ 25.0 Long-term lease liabilities Deferred and Other Long-term Liabilities 146.6 168.3 Total lease liabilities $ 171.0 $ 193.3 Other information Weighted-average remaining lease term (years) 9.1 9.7 Weighted-average discount rate 4.3 % 4.3 % Twelve Months Twelve Months Twelve Months Ended Ended Ended December 31, 2021 December 31, 2020 December 31, 2019 Statement of Income Lease cost (1) $ 32.7 $ 27.7 $ 24.6 Twelve Months Twelve Months Ended Ended December 31, 2021 December 31, 2020 Other information Leased assets obtained in exchange for new lease liabilities (2) $ 3.5 $ 50.4 Cash paid for amounts included in the measurement of lease liabilities $ 32.6 $ 25.6 (1) Lease expense is included in cost of sales or SG&A expenses based on the nature of the leased item. Short-term lease expense is excluded from this amount and is not material. The Company also has certain variable leases which are not material. The noncash component of lease expense for the twelve months ended December 31, 2021, 2020 and 2019 was $25.4, $20.1 and $17.9, respectively, is included in the amortization caption in the condensed consolidated statement of cash flows. (2) Leased assets obtained in exchange for new lease liabilities in 2021 primarily consisted of equipment lease additions, partially offset by lease modification terminations. Leased assets obtained in exchange for new lease liabilities in 2020 consisted of $32.4 of real estate lease additions and $18.0 of equipment lease additions, net of modifications. These additions included $24.1 for an agreement between the Company and a third-party warehouse provider for warehouse space and equipment. The Company’s minimum annual rentals including reasonably assured renewal options under lease agreements are as follows: Operating Leases 2022 $ 30.9 2023 26.6 2024 24.2 2025 22.7 2026 15.3 2027 and thereafter 91.0 Total future minimum lease commitments 210.7 Less: Imputed Interest (39.7 ) Present value of lease liabilities $ 171.0 |
Accounts Payable and Accrued Ex
Accounts Payable and Accrued Expenses | 12 Months Ended |
Dec. 31, 2021 | |
Payables And Accruals [Abstract] | |
Accounts Payable and Accrued Expenses | 9 . Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following: December 31, December 31, 2021 2020 Trade accounts payable $ 663.8 $ 588.1 Accrued marketing and promotion costs 201.6 177.8 Accrued wages and related benefit costs 87.7 124.2 Other accrued current liabilities 166.6 134.4 Total $ 1,119.7 $ 1,024.5 |
Short-Term Borrowings and Long-
Short-Term Borrowings and Long-Term Debt | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Short-Term Borrowings and Long-Term Debt | 10 . Short-Term Borrowings and Long-Term Debt Short-term borrowings and long-term debt consist of the following: December 31, December 31, 2021 2020 Short-term borrowings Commercial paper issuances $ 249.7 $ 349.0 Various debt due to international banks 3.1 2.4 Total short-term borrowings $ 252.8 $ 351.4 Long-term debt Term loan due May 1, 2022 $ 0.0 $ 300.0 2.45% Senior notes due August 1, 2022 300.0 300.0 Less: Discount 0.0 (0.1 ) 2.875% Senior notes due October 1, 2022 400.0 400.0 Less: Discount (0.1 ) (0.1 ) Term loan due December 22, 2024 400.0 0.0 3.15% Senior notes due August 1, 2027 425.0 425.0 Less: Discount (0.3 ) (0.3 ) 2.3% Senior notes due December 15, 2031 400.0 0.0 Less: Discount (0.8 ) 0.0 3.95% Senior notes due August 1, 2047 400.0 400.0 Less: Discount (2.5 ) (2.6 ) Debt issuance costs, net (11.2 ) (9.4 ) Total long-term debt 2,310.1 1,812.5 Less: current maturities (699.4 ) 0.0 Net long-term debt $ 1,610.7 $ 1,812.5 Revolving Credit Facility On May 1, 2019, the Company amended its $1,000.0 unsecured revolving credit facility (the “Credit Agreement”) to extend the term of the Credit Agreement from March 29, 2023 to March 29, 2024. Under the Credit Agreement, the Company has the ability to increase its borrowing up to an additional $600.0, subject to lender commitments and certain conditions as described in the Credit Agreement. Borrowings under the Credit Agreement are available for general corporate purposes and are used to support the Company’s $1,000.0 commercial paper program. In March 2020, the Company drew down a total amount of $825.0 under the Revolving Credit Facility. The Company initiated borrowings under the Revolving Credit Facility as a precautionary measure to increase its cash position and preserve financial flexibility in light of uncertainty in the global markets resulting from the COVID-19 pandemic. The full $825.0 was repaid in May 2020. Interest on the Company’s borrowings under the Credit Agreement will accrue at a per annum rate equal to the sum of (x) either (at the Company’s option) (i) the adjusted LIBOR rate (generally, the LIBOR rate for an interest period selected by the Company and adjusted for statutory reserves) or (ii) the Base Rate (generally equal to the highest of (a) the Federal Funds Rate plus 0.50%, (b) Bank of America’s “prime rate” and (c) the adjusted LIBOR rate for an interest period of one-month plus 1.00%), in any case not less than zero, plus (y) the applicable margin. The applicable margin is determined based upon the corporate credit rating of the Company and ranges from 0.875% to 1.500% per annum, in the case of any borrowing bearing interest by reference to the adjusted LIBOR rate, and 0% to 0.50%, in the case of any borrowing bearing interest by reference to the Base Rate. In addition, the Company will bear certain customary fees, including a commitment fee, determined based upon the corporate credit rating of the Company and ranging from 0.070% to 0.175% per annum on the aggregate unused commitments under the Credit Agreement, and additional issuance fees and participation fees in respect of any letters of credit issued under the Credit Agreement. The Credit Agreement contains customary affirmative and negative covenants, including without limitation, restrictions on the indebtedness, liens, investments, asset dispositions, fundamental changes, changes in the nature of the business conducted, affiliate transactions, burdensome agreements and use of proceeds. Under the Credit Agreement, the Company is required to maintain its leverage ratio, defined as the ratio of its Consolidated Funded Indebtedness (as defined in the Credit Agreement) to EBITDA, at a level no greater than 3.75 to 1.00 (or, to the extent the Company or any Subsidiary has consummated a material acquisition, (i) at a level no greater than 4.25:1.00 for the 12 month period commencing on the date the Company or any Subsidiary consummates the first material acquisition after the closing date and (ii) at a level no greater than 4.25:1.00 for the 12 month period commencing on the date the Company or any Subsidiary consummates any additional material acquisition, provided that the Company has maintained a leverage ratio of 3.75:1.00 or less during each of the immediately preceding four consecutive fiscal quarters before the date of such additional material acquisition). The Credit Agreement also contains customary events of default, including failure to make certain payments under the Credit Agreement when due, breach of covenants, materially incorrect representations and warranties, default on other material indebtedness, events of bankruptcy, material adverse judgments, certain events relating to pension plans, the failure of any of the loan documents to remain in full force and effect and the occurrence of any change in control with respect to the Company. December 22, 2024 Term Loan On December 22, 2021, the Company entered into a $400.0 unsecured term loan facility (the “Term Loan Facility”) with various banks. The loan was fully drawn at closing. Unless prepaid, the loan is due on December 22, 2024. The interest rate is LIBOR plus an applicable margin based on the Company’s credit rating, which can range from 60 basis points (“bps”) to 125 bps. The proceeds of the loan were used to partially fund the TheraBreath Acquisition, with the remaining proceeds used for the repayment of commercial paper. The Term Loan Facility contains customary affirmative and negative covenants, including without limitation, restrictions on the indebtedness, liens, investments, asset dispositions, fundamental changes, changes in the nature of the business conducted, affiliate transactions, burdensome agreements and use of proceeds. Under the Term Loan Facility, the Company is required to maintain its leverage ratio, defined as the ratio of its Consolidated Funded Indebtedness (as defined in the Term Loan Facility) to Consolidated EBITDA, at a level no greater than 3.75 to 1.00 (or, to the extent the Company or any Subsidiary has consummated a material acquisition, (i) at a level no greater than 4.25:1.00 for the 12 month period commencing on the date the Company or any Subsidiary consummates the Acquisition (as defined in the Term Loan Facility) and (ii) at a level no greater than 4.25:1.00 for the 12 month period commencing on the date the Company or any Subsidiary consummates any material acquisition, provided that the Company has maintained a leverage ratio of 3:75:1.00 or less during each of the immediately preceding four consecutive fiscal quarters before the date of such material acquisition). The Term Loan Facility also contains customary events of default, including failure to make certain payments under the Term Loan Facility when due, breach of covenants, materially incorrect representations and warranties, default on other material indebtedness, events of bankruptcy, material adverse judgments, certain events relating to pension plans, the failure of any of the loan documents to remain in full force and effect and the occurrence of any change in control with respect to the Company. 2.3% Senior Notes The Company financed the TheraBreath Acquisition with a portion of the proceeds from an underwritten public offering of $400.0 aggregate principal amount Senior Notes due 2031 (the “2031 Notes”). These Notes bear interest at 2.3% and were issued in an underwritten offering under an indenture with Deutsche Bank Trust Company Americas, as trustee. Interest on the 2031 Notes is payable semi-annually, on each June 15 and December 15. The 2031 Notes will mature on December 15, 2031, unless earlier retired or redeemed. $1.425M Senior Notes The Company financed the Waterpik Acquisition with a portion of the proceeds from an underwritten public offering of $1,425.0 aggregate principal amount of Senior Notes completed on July 25, 2017, consisting of $300.0 aggregate principal amount of Floating Rate Senior Notes that were due in 2019 and fully repaid, $300.0 aggregate principal amount of 2.45% Senior Notes due 2022, $425.0 aggregate principal amount of 3.15% Senior Notes due 2027 and $400.0 aggregate principal amount of 3.95% Senior Notes due 2047 (collectively 2.875% Senior Notes On September 26, 2012, the Company issued $400.0 aggregate principal amount of 2.875% Senior Notes due 2022 (the “2022 Notes”). These Notes were issued under the second supplemental indenture dated September 26, 2012 (the “BNY Mellon Second Supplemental Indenture”) to the indenture dated December 15, 2010 (the “BNY Mellon Base Indenture”) between the Company and The Bank of New York Mellon Trust Company, N.A. (“BNY Mellon”), as trustee. Interest on the 2022 Notes is payable semi-annually, on each April 1 and October 1. The 2022 Notes will mature on October 1, 2022, unless earlier retired or redeemed. May 1, 2022 Term Loan On May 1, 2019, the Company entered into a $300.0 unsecured term loan credit facility with various banks, the proceeds of which were used to partially fund the Flawless Acquisition. The interest rate was LIBOR plus an applicable margin based on the Company’s credit rating, which can range from 60 basis points (“bps”) to 125 bps. In June 2021, the Company repaid $100.0 principal of the $300.0 term loan due May 1, 2022, with the remaining $200.0 principal repaid in early July 2021. The term loan was repaid with proceeds from commercial paper borrowings and cash on hand. Commercial Paper The Company has an agreement with four banks to establish a commercial paper program (the “Program”). Under the Program, the Company may issue notes from time to time up to an aggregate principal amount outstanding at any given time of $1,000.0. Interest Rate Swap Lock Agreement The Company entered into interest rate swap lock agreements to hedge the risk of changes in the interest payments attributable to changes in the benchmark LIBOR interest rate associated with anticipated issuances of debt. These interest rate swap lock agreements have been designated as cash flow hedges and have a notional amount of $300.0. The fair value of these interest rate swap lock agreements is reflected in the Consolidated Balance Sheet within Accounts Payable and Accrued Expenses. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 1 1 . Income Taxes The components of income before taxes are as follows: 2021 2020 2019 Domestic $ 958.6 $ 921.6 $ 726.7 Foreign 73.1 52.2 47.0 Total $ 1,031.7 $ 973.8 $ 773.7 The following table summarizes the provision for U.S. federal, state and foreign income taxes: 2021 2020 2019 Current: U.S. federal $ 130.6 $ 114.2 $ 117.2 State 34.1 32.1 24.9 Foreign 19.2 15.9 10.1 183.9 162.2 152.2 Deferred: U.S. federal 16.5 22.9 3.6 State 4.5 4.2 (0.5 ) Foreign (0.7 ) (1.4 ) 2.5 20.3 25.7 5.6 Total provision $ 204.2 $ 187.9 $ 157.8 Deferred tax assets (liabilities) consist of the following at December 31: 2021 2020 Deferred tax assets: Accounts receivable $ 8.6 $ 6.8 Deferred compensation 52.0 48.6 Pension, postretirement and postemployment benefits 6.1 6.3 Other 23.3 19.9 Tax credit carryforwards/other tax attributes 2.9 17.9 International operating loss carryforwards 8.2 8.7 Interest rate swaps 10.3 14.2 Total gross deferred tax assets 111.4 122.4 Valuation allowances (13.1 ) (22.6 ) Total deferred tax assets 98.3 99.8 Deferred tax liabilities: Goodwill (270.2 ) (226.9 ) Trade names and other intangibles (508.5 ) (520.4 ) Property, plant and equipment (55.5 ) (56.1 ) Total deferred tax liabilities (834.2 ) (803.4 ) Net deferred tax liability $ (735.9 ) $ (703.6 ) Long term net deferred tax asset 9.2 3.7 Long term net deferred tax liability (745.1 ) (707.3 ) Net deferred tax liability $ (735.9 ) $ (703.6 ) The difference between tax expense and the tax that would result from the application of the federal statutory rate is as follows: 2021 2020 2019 Statutory rate 21 % 21 % 21 % Tax that would result from use of the federal statutory rate $ 216.6 $ 204.5 $ 162.4 State and local income tax, net of federal effect 30.5 28.7 19.3 Varying tax rates of foreign affiliates 2.6 2.8 1.8 Valuation Allowances (8.5 ) 2.9 0.9 Stock Options Exercised (29.0 ) (29.4 ) (16.1 ) Worthless Stock Deduction - Investment in Brazil 0.0 0.0 (12.0 ) Reserve for Uncertain Tax Position - Investment in Brazil 0.0 (10.6 ) 12.0 Other (8.0 ) (11.0 ) (10.5 ) Recorded tax expense $ 204.2 $ 187.9 $ 157.8 Effective tax rate 19.8 % 19.3 % 20.4 % At December 31, 2021, certain foreign subsidiaries of the Company had net operating loss carryforwards of approximately $25.1. The net operating loss carryforwards are not subject to expiration. The Company believes that it is more likely than not that the benefit from these net operating loss carryforwards will not be realized. In recognition of this risk, the Company has provided a valuation allowance of $8.1 and $8.7 at December 31, 2021 and 2020, respectively, on the deferred tax asset relating to these net operating loss carryforwards. The Company also believes that it is more likely than not that the benefit from certain additional deferred tax assets of a foreign subsidiary will not be realized. In recognition of this risk, the Company maintains a valuation allowance of $0.9 and $1.3 at December 31, 2021 and 2020, respectively, on these deferred tax assets. As of December 31, 2020 the Company maintained a valuation allowance of $12.6 relating to certain foreign tax credit carryforwards which were determined not more likely than not to be realized. During 2021, the Company determined that it was able to utilize approximately $8.5 in foreign tax credits in 2018, 2019, and 2020, resulting in a reduction in the valuation allowance, and a corresponding tax benefit. Accordingly, the Company filed amended returns with the IRS claiming refunds for 2018 and 2019, totaling $6.5, and utilized $2.0 of foreign tax credits in 2020. The Company determined that it is not more likely than not that the remaining benefit from certain foreign tax credit carryforwards will be realized. In recognition of this risk, the Company maintained a valuation allowance of $4.1 at December 31, 2021, on the deferred tax asset relating to these foreign tax credit carryforwards. The Company does not have any undistributed earnings of foreign subsidiaries that are considered to be indefinitely reinvested outside of the U.S. The Company has recorded liabilities in connection with uncertain tax positions, which, although supportable by the Company, may be challenged by tax authorities. Under applicable accounting guidance, these tax positions do not meet the minimum threshold required for the related tax benefit to be recognized in the income statement. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: 2021 2020 2019 Unrecognized tax benefits at January 1 $ 7.3 $ 18.9 $ 4.7 Gross increases - tax positions in current period 0.3 0.0 13.2 Gross increases - tax positions in prior period 0.8 1.6 1.4 Gross decreases - tax positions in prior period 0.0 (11.8 ) 0.0 Decreases due to settlements and payments 0.0 (1.4 ) 0.0 Lapse of statute of limitations (3.7 ) 0.0 (0.4 ) Unrecognized tax benefits at December 31 $ 4.7 $ 7.3 $ 18.9 During 2019 the Company ceased conducting business in Brazil and recorded a $12.0 reserve for an uncertain tax position relating to a worthless stock deduction for its investment in Brazil. The Company requested a ruling from the IRS in connection with the worthless stock deduction. During 2020 the Company reached a settlement with the IRS for $1.4 relating to the worthless stock deduction and released the related $12.0 reserve, which resulted in a $10.6 income tax benefit. Included in the balance of unrecognized tax benefits at December 31, 2021, December 31, 2020 and December 31, 2019 are $4.1, $6.2 and $18.0, respectively, of tax benefits that, if recognized, would affect the effective tax rate. Also included in the balance of unrecognized tax benefits at December 31, 2021, December 31, 2020 and December 31, 2019 are $0.6, $1.1 and $0.9, respectively, of tax benefits that, if recognized, would result in adjustments to deferred taxes. The Company is subject to U.S. federal income tax as well as income tax in multiple state and international jurisdictions. The Company’s U.S. federal income tax returns are closed for tax years through 2017. The Company is currently under audit by several state taxing authorities for the years 2016 through 2017. It is reasonably possible that a decrease of approximately $0.7 in the unrecognized tax benefits may occur within the next twelve months related to the settlement of these audits or the lapse of applicable statutes of limitations. The Company’s policy for recording interest associated with income tax examinations is to record interest as a component of Income before Income Taxes. During the twelve months ended December 31, 2021, December 31, 2020, and December 31, 2019, the Company recognized interest expense associated with uncertain tax positions of approximately $0.5, $0.4 and $0.4, respectively. As of December 31, 2021, December 31, 2020, and December 31, 2019 the Company had accrued interest expense related to unrecognized tax benefits of $0.5, $1.0 and $0.6, respectively. |
Stock Based Compensation Plans
Stock Based Compensation Plans and Other Benefit Plans | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Stock Based Compensation Plans and Other Benefit Plans | 12. Stock Based Compensation Plans and Other Benefit Plans The Company has non-qualified options outstanding under the Company’s Amended and Restated Omnibus Equity Plan. Under the Amended and Restated Omnibus Equity Plan, the Company may grant stock options and other stock-based awards to employees and directors. The Company has previously sponsored the 1983 Stock Option Plan and the Stock Award Plan, under which the company granted stock options to key management employees, and the Stock Option Plan for Directors, under which the Company granted stock options to non-employee directors. Following approval of the original Omnibus Equity Plan by stockholders in 2008, no further grants were permitted under any of the other equity compensation plans. Stock options outstanding under the plans are issued at market value on the date of grant (with the exception of options granted to former WATERPIK employees as part of the Waterpik Acquisition), vest on the third anniversary of the date of grant and must be exercised within 10 years of the date of grant. No stock options are currently outstanding under the 1983 Stock Option Plan, the Stock Award Plan, or the Stock Option Plan for Directors. If, upon termination of a participant’s employment (other than a termination for cause), a participant is at least 55 years old, has at least five years of service, and the sum of the participant’s age and years of service is at least 65, the participant may exercise any stock options granted between 2007 through 2017 within a period of three years from the date of termination or, if earlier, the date such stock options otherwise would have expired, subject to specified conditions. Starting with stock options granted in 2018, a terminated employee who meets the above conditions may exercise any stock options within a period of ten years from the date of termination or, if earlier, the date such stock options otherwise would have expired, subject to specified conditions. Stock option transactions for the year ended December 31, 2021 were as follows: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Price Term Value Outstanding as of December 31, 2020 12.7 $ 50.72 Granted 1.5 84.71 Exercised (2.8 ) 35.48 Cancelled (0.1 ) 75.48 Outstanding as of December 31, 2021 11.3 $ 58.83 6.1 $ 493.3 Exercisable as of December 31, 2021 6.7 $ 44.80 4.3 $ 380.5 The following table summarizes information relating to options outstanding and exercisable as of December 31, 2021: Options Outstanding Options Exercisable Weighted Weighted Weighted Outstanding Average Average Exercisable Average Range of as of Remaining Exercise as of Exercise Exercise Prices 12/31/2021 Contractual Price 12/31/2021 Price $20.01 - $30.00 0.2 0.5 $ 26.98 0.2 $ 26.98 $30.01 - $40.00 1.3 2.2 $ 33.93 1.3 $ 33.93 $40.01 - $50.00 2.4 3.9 $ 44.07 2.4 $ 44.07 $50.01 - $60.00 2.7 6.0 $ 51.98 2.7 $ 51.98 $60.01 - $70.00 0.1 6.9 $ 65.52 0.1 $ 65.52 $70.01 - $80.00 3.1 8.0 $ 75.36 0.0 $ - $80.01 - $90.00 1.5 9.5 $ 84.70 0.0 $ - 11.3 6.1 $ 58.83 6.7 $ 44.80 The table above represents the Company’s estimate of stock options fully vested and expected to vest. Expected forfeitures are not material and, therefore, are not reflected in the table above. The following table provides information regarding the intrinsic value of stock options exercised and stock compensation expense related to stock option awards: 2021 2020 2019 Intrinsic Value of Stock Options Exercised $ 157.3 $ 159.8 $ 93.1 Stock Compensation Expense Related to Stock Option Awards $ 23.3 $ 21.1 $ 20.3 Issued Stock Options 1.5 1.9 1.5 Weighted Average Fair Value of Stock Options issued (per share) $ 17.32 $ 12.85 $ 14.90 Fair Value of Stock Options Issued $ 26.6 $ 24.5 $ 22.1 The following table provides a summary of the assumptions used in the valuation of issued stock options: 2021 2020 2019 Risk-free interest rate 1.3 % 0.5 % 2.0 % Expected life in years 7.2 7.3 7.3 Expected volatility 20.7 % 19.9 % 17.2 % Dividend yield 1.2 % 1.3 % 1.2 % The fair value of stock options is based upon the Black Scholes option pricing model. The Company determined the stock options’ lives based on historical exercise behavior and their expected volatility and dividend yield based on the historical changes in stock price and dividend payments. The risk-free interest rate is based on the yield of an applicable term Treasury instrument. As of December 31, 2021, there was a fair value of $19.0 related to unamortized stock option compensation expense, which is expected to be recognized over the next three years. The Company’s Consolidated Statements of Cash Flow reflect an add back to Net Cash Provided by Operating Activities of $23.7, $21.5 and $20.8 in 2021, 2020 and 2019, respectively, for non-cash compensation expense, primarily stock option expense. In January 2021, the Company issued cash-settled stock units under the Amended and Restated Omnibus Equity Plan to all employees at the level of vice president and below. These restricted stock units are scheduled to vest and be settled on the third anniversary of the date of grant. In May 2018, the Company issued cash-settled stock units under the Amended and Restated Omnibus Equity Plan to all employees at the level of vice president and below. These restricted stock units were scheduled to vest and be settled on the third anniversary of the date of grant. In December 2020, the Company accelerated the grant to vest in December 2020. As a result of the issued cash-settled stock units, the Company recorded stock compensation expense of $1.9, $3.1 and $1.5 in 2021, 2020 and 2019, respectively. The liability was approximately $1.9 as of December 31, 2021, and there was no liability as of December 31, 2020. Other Benefit Plans Deferred Compensation Plans The Company maintains a non-qualified deferred compensation plan under which certain members of management are eligible to defer a maximum of 85% of their regular compensation (i.e., salary) and, in general, up to 85% of their incentive bonus. The amounts deferred under this plan are credited with earnings or losses based upon changes in values of notional investments selected by the plan participant. The investment options available include notional investments in various stock, bond and money market funds as well as the Company’s Common Stock. Each plan participant is fully vested in the amounts the participant defers. The plan permits the Company to make profit sharing contributions that cannot otherwise be contributed to the qualified savings and profit sharing plan due to limitations established by the Internal Revenue Service. These contributions vest under the same vesting schedule applicable to the qualified plan. The liability to plan participants for contributions designated for notional investment in Common Stock is based on the quoted fair value of the Common Stock plus any dividends credited. The Company uses cash-settled hedging instruments to minimize the cost related to the volatility of Common Stock. At December 31, 2021 and 2020, the amount of the Company’s liability under the deferred compensation plan is included in Current and Deferred and Other Long-term Liabilities and was $131.9 and $116.9, respectively and the funded balances recorded in Other Assets amounted to $107.3 and $101.4, respectively. The amounts charged to earnings, including the effect of the hedges, totaled expense of $2.2 in 2021, expense of $2.1 in 2020 and income of $1.0 in 2019, respectively. Non-employee members of the Company’s Board are eligible to defer up to 100% of their directors’ compensation into a similar plan; however, the only option for investment is Common Stock. Members of the Board are fully vested in their account balance. As of December 31, 2021, there were approximately 149,000 shares of Common Stock from shares held as Treasury Stock in a rabbi trust to protect the interest of the directors’ deferred compensation plan participants in the event of a change of control. |
Share Repurchases
Share Repurchases | 12 Months Ended |
Dec. 31, 2021 | |
Payments For Repurchase Of Equity [Abstract] | |
Share Repurchases | 1 3 . Share Repurchases On November 1, 2017, the Board authorized a share repurchase program, under which the Company may repurchase up to $500.0 in shares of Common Stock (the “2017 Share Repurchase Program”). In December 2020, the Company entered into an accelerated share repurchase (“ASR”) contract with a commercial bank to purchase Common Stock. The Company paid $300.0 to the bank, inclusive of fees, and received an initial delivery of shares equal to $270.0, or 3.1 million shares. The Company used cash on hand and short-term borrowings to fund the initial purchase price. Upon the completion of the ASR, which ended in February 2021, the bank delivered an additional 0.4 million shares to the Company. The final shares delivered to the Company were determined by the average price per share paid by the bank during the purchase period. All 3.5 million shares were purchased under the Company’s evergreen program. In August 2021, the Company executed an agreement to purchase up to $200.0 of its Common Stock through October 31, 2021. The Company purchased 1.6 million shares for approximately $130.0 through October, inclusive of fees, all of which was purchased under the 2017 Share Repurchase Program. On October 28, 2021, the Board authorized a new share repurchase program, under which the Company may repurchase up to $1,000.0 in shares of Common Stock (the “2021 Share Repurchase Program”). The 2021 Share Repurchase Program does not have an expiration and replaced the 2017 Share Repurchase Program. All remaining dollars authorized for repurchase under the 2017 Share Repurchase Plan have been cancelled. The 2021 Share Repurchase Program did not modify the Company’s evergreen share repurchase program, authorized by the Board on January 29, 2014, under which the Company may repurchase, from time to time, Common Stock to reduce or eliminate dilution associated with issuances of Common Stock under its incentive plans. In December 2021, the Company executed open market purchases of 1.8 million shares for $170.3, inclusive of fees, of which $100.0 In December 2021, the Company also entered into an accelerated share repurchase contract with a commercial bank to purchase Common Stock. The Company paid $200.0 to the bank, inclusive of fees, and received an initial delivery of shares equal to $180.0, or 1.8 million shares. The Company used cash on hand and short-term borrowings to fund the initial purchase price. Upon the completion of the ASR, which ended in February 2022, the bank delivered an additional 0.2 million shares to the Company. The final shares delivered to the Company were determined by the average price per share paid by the bank during the purchase period. All 2.0 million shares were purchased under the 2021 Share Repurchase Program . As a result of the Company’s recent stock repurchases, there remains $729.7 of share repurchase availability under the 2021 Share Repurchase Program as of December 31, 2021. |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Income (Loss) | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Accumulated Other Comprehensive Income (Loss) | 1 4 . Accumulated Other Comprehensive Income (Loss) Comprehensive income is defined as net income and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. The components of changes in accumulated other comprehensive income (“AOCI”) are as follows: Accumulated Foreign Defined Other Currency Benefit Derivative Comprehensive Adjustments Plans Agreements Income (Loss) Balance December 31, 2018 $ (42.5 ) $ 0.9 $ (12.0 ) $ (53.6 ) Other comprehensive income before reclassifications 3.8 (1.3 ) (30.2 ) (27.7 ) Amounts reclassified to consolidated statement of income (a) 1.9 0.0 6.1 8.0 Tax benefit (expense) 0.0 0.4 6.2 6.6 Other comprehensive income (loss) 5.7 (0.9 ) (17.9 ) (13.1 ) Balance December 31, 2019 $ (36.8 ) $ 0.0 $ (29.9 ) $ (66.7 ) Other comprehensive income (loss) before reclassifications 10.4 0.0 (34.8 ) (24.4 ) Amounts reclassified to consolidated statement of income (a) 0.0 0.0 5.8 5.8 Tax benefit (expense) 0.0 0.0 7.7 7.7 Other comprehensive income (loss) 10.4 0.0 (21.3 ) (10.9 ) Balance December 31, 2020 $ (26.4 ) $ 0.0 $ (51.2 ) $ (77.6 ) Other comprehensive income (loss) before reclassifications (3.8 ) (0.8 ) 26.7 22.1 Amounts reclassified to consolidated statement of income (a) 0.0 0.0 (8.2 ) (8.2 ) Tax benefit (expense) 0.0 0.2 (4.7 ) (4.5 ) Other comprehensive income (loss) (3.8 ) (0.6 ) 13.8 9.4 Balance December 31, 2021 $ (30.2 ) $ (0.6 ) $ (37.4 ) $ (68.2 ) ( a ) Amounts reclassified to cost of sales, selling, general and administrative expenses, or interest expense. |
Commitments, Contingencies and
Commitments, Contingencies and Guarantees | 12 Months Ended |
Dec. 31, 2021 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments, Contingencies and Guarantees | 1 5 . Commitments, Contingencies and Guarantees Commitments a. The Company has a partnership with a supplier of raw materials that mines and processes sodium-based mineral deposits. The Company purchases the majority of its sodium-based raw material requirements from the partnership. The partnership agreement terminates upon two years’ written notice by either partner. Under the partnership agreement, the Company has an annual commitment to purchase 240,000 tons of sodium-based raw materials at the prevailing market price. The Company is not engaged in any other material transactions with the partnership or the partner supplier. b. As of December 31, 2021, the Company had commitments of approximately $362.6. These commitments include the purchase of raw materials, packaging supplies and services from its vendors at market prices to enable the Company to respond quickly to changes in customer orders or requirements, as well as costs associated with licensing and promotion agreements. c. As of December 31, 2021, the Company had various guarantees and letters of credit totaling $4.7. d. In connection with the Company’s acquisition of Agro BioSciences, Inc. on January 17, 2017, the Company was obligated to pay an additional amount of up to $25.0 based on sales performance in 2019. The initial fair value of this liability was $17.8, which was established in the purchase price allocation. In December 2019, the liability was lowered to $ 14.2 based on 2019 sales . The reduction was recorded in SG&A in the SPD segment. In April 2020, a payment of $ 14.5 was paid to settle the liability . In connection with the Passport Acquisition, the Company was obligated to pay an additional amount of up to $25.0 based on sales performance through 2020. The initial fair value of this business acquisition business acquisition business acquisition In connection with the Flawless Acquisition, the Company was obligated to pay an additional amount of up to $425.0 based on sales performance through 2021. The initial fair value of this business acquisition business acquisition In connection with the Zicam Acquisition, the Company deferred an additional cash payment of $20.0 related to certain indemnifications provided by the seller. The additional amount is payable five years from the closing. In connection with the TheraBreath Acquisition, the Company deferred an additional cash payment of $14.0 related to certain indemnity obligations Legal proceedings e. In addition, in conjunction with the Company’s acquisition and divestiture activities, the Company entered into select guarantees and indemnifications of performance with respect to the fulfillment of the Company’s commitments under applicable purchase and sale agreements. The arrangements generally indemnify the buyer or seller for damages associated with breach of contract, inaccuracies in representations and warranties surviving the closing date and satisfaction of liabilities and commitments retained under the applicable contract. Representations and warranties that survive the closing date generally survive for periods up to five years or the expiration of the applicable statutes of limitations. Potential losses under the indemnifications are generally limited to a portion of the original transaction price, or to other lesser specific dollar amounts for select provisions. With respect to sale transactions, the Company also routinely enters into non-competition agreements for varying periods of time. Guarantees and indemnifications with respect to acquisition and divestiture activities, if triggered, could have a materially adverse impact on the Company’s financial condition, results of operations and cash flows. f. In addition to the matters described above, from time to time in the ordinary course of its business the Company is the subject of, or party to, various pending or threatened legal, regulatory or governmental actions or other proceedings, including, without limitation, those relating to, intellectual property, commercial transactions, product liability, purported consumer class actions, employment matters, antitrust, environmental, health, safety and other compliance related matters. Such proceedings are generally subject to considerable uncertainty and their outcomes, and any related damages, may not be reasonably predictable or estimable. Any such proceedings could result in a material adverse outcome negatively impacting the Company’s business, financial condition, results of operations or cash flows. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 1 6 . Related Party Transactions The following summarizes the balances and transactions between the Company and each of Armand and ArmaKleen, in which the Company holds a 50% Armand ArmaKleen Year Ended December 31, Year Ended December 31, 2021 2020 2019 2021 2020 2019 Purchases by Company $ 12.9 $ 14.2 $ 14.3 $ 0.0 $ 0.0 $ 0.0 Sales by Company $ 0.0 $ 0.0 $ 0.0 $ 1.2 $ 1.1 $ 1.1 Outstanding Accounts Receivable $ 1.0 $ 0.7 $ 0.6 $ 0.9 $ 0.5 $ 0.8 Outstanding Accounts Payable $ 1.2 $ 1.4 $ 1.6 $ 0.0 $ 0.0 $ 0.0 Administration & Management Oversight Services (1) $ 2.2 $ 2.1 $ 2.7 $ 2.1 $ 2.2 $ 2.1 (1) Billed by Company and recorded as a reduction of SG&A expenses. |
Segments
Segments | 12 Months Ended |
Dec. 31, 2021 | |
Segment Reporting [Abstract] | |
Segments | 1 7 . Segments Segment Information The Company operates three reportable segments: Consumer Domestic, Consumer International and Specialty Products Division. These segments are determined based on differences in the nature of products and organizational and ownership structures. The Company also has a Corporate segment. Segment revenues are derived from the sale of the following products: Segment Products Consumer Domestic Household and personal care products Consumer International Primarily personal care products SPD Specialty chemical products The Corporate segment income consists of equity in earnings of affiliates. As of December 31 50% Certain subsidiaries that are included in the Consumer International segment manufacture and sell personal care products to the Consumer Domestic segment. These sales are eliminated from the Consumer International segment results set forth in the table below. The following table presents selected financial information relating to the Company’s segments for each of the three years in the period ended December 31, 2021: Consumer Consumer Domestic International SPD Corporate (1) As Net sales 2021 $ 3,941.9 $ 912.2 $ 336.0 $ 0.0 $ 5,190.1 2020 3,767.6 828.2 300.0 0.0 4,895.8 2019 3,302.6 756.3 298.8 0.0 4,357.7 Gross profit 2021 1,795.8 402.1 112.7 (47.1 ) 2,263.5 2020 1,801.1 368.8 104.1 (59.8 ) 2,214.2 2019 1,575.2 346.1 110.9 (48.2 ) 1,984.0 Marketing Expenses 2021 442.1 131.1 4.5 0.0 577.7 2020 460.6 126.9 3.7 0.0 591.2 2019 398.0 112.9 4.1 0.0 515.0 Selling, General and Administrative Expenses 2021 445.3 135.7 72.8 (47.1 ) 606.7 2020 455.6 128.7 68.8 (59.8 ) 593.3 2019 470.1 151.7 55.2 (48.2 ) 628.8 Income from Operations 2021 908.4 135.3 35.4 0.0 1,079.1 2020 884.9 113.2 31.6 0.0 1,029.7 2019 707.1 81.5 51.6 0.0 840.2 Equity in Earnings of Affiliates 2021 0.0 0.0 0.0 9.4 9.4 2020 0.0 0.0 0.0 6.7 6.7 2019 0.0 0.0 0.0 6.6 6.6 Income Before Income Taxes 2021 861.4 127.3 33.6 9.4 1,031.7 2020 832.4 105.0 29.7 6.7 973.8 2019 645.8 74.0 47.3 6.6 773.7 Identifiable Assets 2021 6,354.5 1,192.9 332.7 116.4 7,996.5 2020 5,819.8 1,144.5 339.7 110.5 7,414.5 2019 5,099.1 1,110.0 340.4 107.9 6,657.4 Capital Expenditures 2021 100.3 8.4 10.1 0.0 118.8 2020 81.8 7.1 10.0 0.0 98.9 2019 53.9 9.4 10.4 0.0 73.7 Depreciation & Amortization 2021 170.0 31.1 15.4 2.6 219.1 2020 142.8 29.6 14.5 2.8 189.7 2019 131.9 27.1 14.1 3.3 176.4 (1) Corporate reflects the following: (A) (B) (C) Other than the differences noted in the footnote above, the accounting policies followed by each of the segments, including intersegment transactions, are substantially consistent with the accounting policies described in Note 1. Intersegment sales from Consumer International to Consumer Domestic, which are not reflected in the table above, were $10.8, $11.7 and $10.5 for the twelve months ended December 31, 2021, December 31, 2020 and December 31, 2019, respectively. Product line revenues from external customers for each of the three years ended December 31, 2021, December 31, 2020 and December 31, 2019 were as follows: 2021 2020 2019 Household Products $ 2,103.0 $ 2,038.5 $ 1,821.7 Personal Care Products 1,838.9 1,729.1 1,480.9 Total Consumer Domestic 3,941.9 3,767.6 3,302.6 Total Consumer International 912.2 828.2 756.3 Total SPD 336.0 300.0 298.8 Total Consolidated Net Sales $ 5,190.1 $ 4,895.8 $ 4,357.7 Household Products include laundry, deodorizing, and cleaning products. Personal Care Products include condoms, pregnancy kits, oral care products, skin care products, hair care products and gummy dietary supplements. Geographic Information Approximately 82%, 83% and 82% of the net sales reported in the accompanying consolidated financial statements in 2021, 2020 and 2019, respectively, were to customers in the U.S. Approximately 96%, 96% and 95% of long-lived assets were located in the U.S. at December 31, 2021, 2020 and 2019, respectively. Other than the U.S., no one country accounts for more than 5% of consolidated net sales and 5% of total assets. Customers A group of three customers accounted for approximately 37% of consolidated net sales in 2021 and 36% |
SCHEDULE II-Valuation and Quali
SCHEDULE II-Valuation and Qualifying Accounts | 12 Months Ended |
Dec. 31, 2021 | |
Valuation And Qualifying Accounts [Abstract] | |
SCHEDULE II-Valuation and Qualifying Accounts | SCHEDULE II - Valuation and Qualifying Accounts For each of the three years in the period ended December 31, 2021 (Dollars in millions) Additions Deductions Beginning Charged to Amounts Foreign Ending Balance Expenses Acquired Written Off Exchange Balance Allowance for Doubtful Accounts 2021 $ 3.7 $ 0.6 $ 1.9 $ (0.7 ) $ 0.0 $ 5.5 2020 2.4 1.4 0.0 (0.1 ) 0.0 3.7 2019 3.1 0.4 0.0 (1.1 ) 0.0 2.4 Allowance for Cash Discounts 2021 $ 6.0 $ 98.4 $ 0.0 $ (98.5 ) $ 0.0 $ 5.9 2020 5.1 96.0 0.4 (95.5 ) 0.0 6.0 2019 5.0 86.9 0.0 (86.8 ) 0.0 5.1 Sales Returns and Allowances 2021 $ 24.5 $ 129.4 $ 0.0 $ (121.5 ) $ 0.0 $ 32.4 2020 13.0 110.9 0.4 (99.8 ) 0.0 24.5 2019 12.1 97.2 0.0 (96.4 ) 0.1 13.0 |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying Consolidated Financial Statements are presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and include the accounts of the Company and its majority‑owned subsidiaries. For equity investments in which the Company does not control or have the ability to exert significant influence over the investee, which generally is when the Company has less than a 20% ownership interest, the investments are accounted for under the cost method. In circumstances where the Company has greater than a 20% ownership interest and has the ability to exercise significant influence over, but does not control, the investee, the investment is accounted for under the equity method. As a result, the Company accounts for its 50% interest in its Armand Products Company (“Armand”) joint venture and its 50% interest in The ArmaKleen Company (“ArmaKleen”) joint venture under the equity method. Armand and ArmaKleen are specialty chemical businesses. The Company’s equity in earnings of Armand and ArmaKleen are included in the Corporate segment, as described in Note 16. |
Use Of Estimates | Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent gains and losses at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Management makes estimates regarding inventory valuation, promotional and sales returns reserves, the carrying amount of goodwill and other intangible assets, the realization of deferred tax assets, tax reserves, business acquisition liabilities, liabilities related to other postretirement benefit obligations and other matters that affect the reported amounts and other disclosures in the financial statements. These estimates are based on judgment and available information. Actual results could differ materially from those estimates, and it is possible that changes in such estimates could occur in the near term. |
Revenue Recognition | Revenue Recognition Revenue is recognized when control of a promised good is transferred to a customer in an amount that reflects the consideration that the Company expects to be entitled to in exchange for that good. This usually occurs when finished goods are delivered to the Company’s customers or when finished goods are picked up by a customer or a customer’s carrier. a. Nature of Goods and Services The Company primarily ships finished goods to its customers and operates in three segments: Consumer Domestic, Consumer International and Specialty Products Division (“SPD”). The segments are based on differences in the nature of products and organizational and ownership structures. The Consumer Domestic and Consumer International segments market a variety of personal care and household products and over-the-counter products, including but not limited to baking soda, cat litter, laundry detergent, condoms, stain removers, hair removal, gummy dietary supplements, dry shampoo, water flossers and showerheads. The SPD segment focuses on sales to businesses and participates in three product areas: Animal and Food Production, Specialty Chemicals and Specialty Cleaners. The Company’s products are distinct and separately identifiable on customer contracts or invoices, with each product sale representing a separate performance obligation. The Company sells consumer products under a variety of brands through a broad distribution platform that includes supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar, pet and other specialty stores and websites and other e-commerce channels, all of which sell its products to consumers. The Company sells its specialty products to industrial customers, livestock producers and through distributors. Refer to Note 17 for disaggregated revenue information with respect to each of the Company’s segments. b. When Performance Obligations are Satisfied For performance obligations related to the shipping and invoicing of products, control transfers at the point in time upon which finished goods are delivered to the Company’s customers or when finished goods are picked up by a customer or a customer’s carrier. Once a product has been delivered or picked up by the customer, the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset. The Company considers control to have transferred upon delivery or customer receipt because the Company has an enforceable right to payment at that time, the customer has legal title to the asset, the Company has transferred physical possession of the asset, and the customer has significant risk and rewards of ownership of the asset. c. Variable Consideration The Company conducts extensive promotional activities, primarily through the use of off-list discounts, slotting, coupons, cooperative advertising, periodic price reduction arrangements, and end-aisle and other in-store displays. The costs of such activities are netted against sales and are recorded when the related sale takes place. The reserves for sales returns and consumer and trade promotion liabilities are established based on the Company’s best estimate of the amounts necessary to settle future and existing obligations for products sold as of the balance sheet date. The Company uses historical trend experience and coupon redemption inputs in arriving at coupon reserve requirements, and uses forecasted appropriations, customer and sales organization inputs, and historical trend analysis in determining the reserves for other promotional activities and sales returns. d. Practical Expedients The Company expenses incremental direct costs of obtaining a contract (broker commissions) when the related sale takes place. These costs are recorded in SG&A expenses in the accompanying consolidated statements of income. The Company accounts for shipping and handling costs as fulfillment activities which are therefore recognized upon shipment of the goods. The Company has applied the portfolio approach to all open contracts as they have similar characteristics and can reasonably expect that the effects on the financial statements of applying this new guidance to the portfolio of contracts would not differ materially from applying this guidance to the individual contracts within the portfolio. The Company excludes from its revenue any amounts collected from customers for sales (and similar) taxes. |
Sales of Accounts Receivable | Sales of Accounts Receivable The Company entered into a factoring agreement with a financial institution to sell certain customer receivables at discounted rates in 2015. Transactions under this agreement are accounted for as sales of accounts receivable and are removed from the Consolidated Balance Sheet at the time of the sales transaction. As the customers associated with the Company’s factoring program have been consistent in recent years, the sales performance by customer has driven the amount factored each year. The Company factored an incremental $21.2, $21.1, and $26.0 during the years ended December 31, 2021, 2020 and 2019, respectively. |
Cost of Sales | Cost of Sales, Marketing and Selling, General and Administrative Expenses Cost of sales include costs related to the manufacture of the Company’s products, including raw material, inbound freight, direct labor (including employee compensation benefits) and indirect plant costs such as plant supervision, receiving, inspection, maintenance labor and materials, depreciation, taxes and insurance, purchasing, production planning, operations management, logistics, freight to customers, warehousing costs, internal transfer freight costs and plant impairment charges. |
Marketing | Marketing expenses include costs for advertising (excluding the costs of cooperative advertising programs, which are reflected in net sales), costs for coupon insertion (mainly the cost of printing and distribution), consumer promotion costs (such as on-shelf advertisements and floor ads), public relations, package design expense and market research costs. |
Selling, General and Administrative Expenses | Selling, general and administrative expenses (“SG&A”) expenses include, among others, costs related to functions such as sales, corporate management, research and development, marketing administration, information technology and legal. Such costs include salary compensation related costs (such as benefits, incentive compensation and profit sharing), stock option costs, depreciation, travel and entertainment related expenses, professional and other consulting fees and amortization of intangible assets. |
Foreign Currency Translation | Foreign Currency Translation Unrealized gains and losses related to currency translation are recorded in Accumulated Other Comprehensive Income (Loss). Gains and losses on foreign currency transactions are recorded in the Consolidated Statements of Income. |
Cash Equivalents | Cash Equivalents Cash equivalents consist of highly liquid short-term investments and term bank deposits, which mature within three months of their original maturity date. |
Inventories | Inventories Inventories are valued at the lower of cost or market (net realizable value, which reflects any costs to sell or dispose). The Company identifies any slow moving, obsolete or excess inventory to determine whether an adjustment is required to establish a new carrying value. The determination of whether inventory items are slow moving, obsolete or in excess of needs requires estimates and assumptions about the future demand for the Company’s products, technological changes, and new product introductions. Estimates as to the future demand used in the valuation of inventory involve judgments regarding the ongoing success of the Company’s products. The Company evaluates its inventory levels and expected usage on a periodic basis and records adjustments as required. Adjustments to reflect inventory at net realizable value were $36.2 at December 31, 2021, and $17.0 at December 31, 2020. |
Property, Plant and Equipment | Property, Plant and Equipment Property, Plant and Equipment (“PP&E”) are stated at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets. Estimated useful lives for building and improvements, machinery and equipment, and office equipment range from 9-40, 3-20 and 3-10 years, respectively. Routine repairs and maintenance are expensed when incurred. Leasehold improvements are depreciated over a period no longer than the respective lease term, except where a lease renewal has been determined to be reasonably assured and failure to renew the lease results in a significant penalty to the Company. PP&E is reviewed annually and whenever events or changes in circumstances indicate that possible impairment exists. The Company’s impairment review is based on an undiscounted cash flow analysis at the lowest level at which cash flows of the long-lived assets are largely independent of other groups of Company assets and liabilities. The analysis requires management judgment with respect to changes in technology, the continued success of product lines, and future volume, revenue and expense growth rates. The Company conducts annual reviews to identify idle and underutilized equipment, and reviews business plans for possible impairment. Impairment occurs when the carrying value of the asset exceeds the future undiscounted cash flows. When an impairment is indicated, the estimated future cash flows are then discounted to determine the estimated fair value of the asset and an impairment charge is recorded for the difference between the carrying value and the net present value of estimated future cash flows. |
Software | Software The Company capitalizes certain costs of developing computer software. Amortization is recorded using the straight‑line method over the estimated useful life of the software, which is estimated to be no longer than 10 years. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Certain financial instruments are required to be recorded at fair value. The estimated fair values of such financial instruments (including investment securities and other derivatives) have been determined using market information and valuation methodologies. Changes in assumptions or estimation methods could affect the fair value estimates. Other financial instruments, including cash equivalents and short-term debt, are recorded at cost, which approximates fair value. Additional information regarding the Company’s risk management activities, including derivative instruments and hedging activities, are separately disclosed. See Notes 2 and 3. |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets Carrying values of goodwill and indefinite-lived trade names are reviewed periodically for possible impairment. The Company’s impairment analysis is based on a discounted cash flow approach that requires significant judgment with respect to unit volume, revenue and expense growth rates, and the selection of an appropriate discount rate and royalty rate. Management uses estimates based on expected trends in making these assumptions. With respect to goodwill, impairment occurs when the carrying value of the reporting unit exceeds the discounted present value of cash flows for that reporting unit. For trade names and other intangible assets, an impairment charge is recorded for the difference between the carrying value and the net present value of estimated future cash flows, which represents the estimated fair value of the asset. Judgment is required in assessing whether assets may have become impaired between annual valuations. Indicators such as unexpected adverse economic factors, unanticipated technological change, distribution losses, or competitive activities and acts by governments and courts may indicate that an asset has become impaired. Intangible assets with finite lives are amortized over their estimated useful lives, which range from 3-20 years, using the straight-line method, and reviewed for impairment when changes in market circumstances occur. It is possible that the Company’s conclusions regarding impairment or recoverability of goodwill or other intangible assets could change in future periods if, for example, (i) the businesses or brands do not perform as projected, (ii) overall economic conditions in future years vary from current assumptions (including changes in discount rates), (iii) business conditions or strategies change from current assumptions, (iv) investors require higher rates of return on equity investments in the marketplace or (v) enterprise values of comparable publicly traded companies, or actual sales transactions of comparable companies, were to decline, resulting in lower multiples of revenues and EBITDA. |
Research and Development | Research and Development The Company incurred research and development expenses in the amount of $105.2, $102.6 and $93.6 in 2021, 2020 and 2019, respectively. These expenses are included in SG&A expenses and are expensed as incurred. |
Earnings Per Share ("EPS") | Earnings Per Share (“EPS”) Basic EPS is calculated based on income available to holders of the Company’s common stock (“Common Stock”) and the weighted-average number of shares outstanding during the reported period. Diluted EPS includes additional dilution from potential Common Stock issuable pursuant to the exercise of outstanding stock options. The following table sets forth a reconciliation of the weighted-average number of shares of Common Stock outstanding to the weighted-average number of shares outstanding on a diluted basis: 2021 2020 2019 Weighted average common shares outstanding - basic 244.9 246.8 246.2 Dilutive effect of stock options 4.7 5.4 5.9 Weighted average common shares outstanding - diluted 249.6 252.2 252.1 Antidilutive stock options outstanding 1.6 1.5 1.5 |
Employee and Director Stock Option Based Compensation | Employee and Director Stock Based Compensation The fair value of share-based compensation is determined at the grant date and the related expense is recognized over the required employee service period in which the share-based compensation vests. The following table presents the pre-tax expense associated with the fair value of unvested stock options and restricted stock awards included in SG&A expenses and in cost of sales: For the Year Ended December 31, 2021 2020 2019 Cost of sales $ 3.3 $ 3.6 $ 2.8 Selling, general and administrative expenses 22.3 21.0 19.6 Total $ 25.6 $ 24.6 $ 22.4 |
Income Taxes | Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized to reflect the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the differences are expected to be recovered or settled. Management provides a valuation allowance against deferred tax assets for amounts which are not considered “more likely than not” to be realized. The Company records liabilities for potential assessments in various tax jurisdictions in accordance with GAAP. The liabilities relate to tax return positions that, although supportable by the Company, may be challenged by the tax authorities and do not meet the minimum recognition threshold required under applicable accounting guidance for the related tax benefit to be recognized in the income statement. The Company adjusts this liability as a result of changes in tax legislation, interpretations of laws by courts, rulings by tax authorities, changes in estimates and the expiration of the statute of limitations. Many of the judgments involved in adjusting the liability involve assumptions and estimates that are highly uncertain and subject to change. In this regard, settlement of any issue with, or an adverse determination in litigation against, a taxing authority could require the use of cash and result in an increase in the Company’s annual tax rate. Conversely, favorable resolution of an issue with a taxing authority would be recognized as a reduction to the Company’s annual tax rate. |
New Accounting Pronouncements Adopted and Issued | Recently Adopted Accounting Pronouncements In March 2020, the FASB issued new accounting guidance intended to provide temporary optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (“LIBOR”) and other interbank offered rates to alternative reference rates. This guidance was effective beginning on March 12, 2020, and the Company may apply the amendments prospectively to contract modifications made or relationships entered into or evaluated through December 31, 2022. The adoption of this guidance did not have an impact on the Company’s consolidated financial position, results of operations or cash flows in the current period. The Company will continue to evaluate the impacts of this guidance on future contract modifications through December 31, 2022. In February 2016 and July 2018, the FASB issued new lease accounting guidance, requiring lessees to recognize right-of-use lease assets and lease liabilities on the balance sheet for those leases previously classified as operating leases, with a term greater than a year. The new guidance also expands the required quantitative and qualitative disclosures surrounding leases. The guidance was effective for annual and interim periods beginning after December 15, 2018, and allowed companies to apply the requirements retrospectively, either to all prior periods presented or through a cumulative adjustment in the year of adoption. The Company adopted the new standard on January 1, 2019 using the optional transition method of adoption which permits the entity to continue presenting all periods prior to January 1, 2019 under the previous lease accounting guidance. The Company has implemented the appropriate internal controls and applications to monitor and record historical and future lease arrangements and required disclosures. For all existing operating leases as of December 31, 2018, the Company recorded Right of Use Assets of approximately $55.0 and corresponding lease liabilities of approximately $57.0 with an offset to Deferred and Other Long-term Liabilities of approximately $2.0 to eliminate deferred rent on the consolidated balance sheet. In addition, based on the transition guidance surrounding failed sale-and-leaseback transactions, the Company re-evaluated the lease for its corporate headquarters in Ewing, New Jersey. This lease was previously considered a failed sale-and-leaseback transaction under Accounting Standards Codification (“ASC”) 840 because of continuing involvement. The re-evaluation resulted in a change in classification from a finance transaction to an operating lease. The corporate headquarters building, which had a net book value of approximately $35.0 recorded in Property, Plant and Equipment as of December 31, 2018, was derecognized on January 1, 2019 and a Right of Use Asset of approximately $52.0 was recorded with an offset to Deferred Income Taxes of $4.0 and Retained Earnings of $13.0. The Lease Liability pertaining to this asset of $52.0 remained unchanged. In total, at the adoption of the new accounting guidance there were Right of Use Assets of approximately $107.0 and a corresponding Lease Liabilities of $109.0. This did not include an existing cease-use liability of approximately $7.0 pertaining to one of the Company’s previous corporate offices that remained unchanged as a result of the transition. Refer to Note 8 for the Company’s lease disclosures. The effects of the recently adopted lease accounting standard to the Company’s consolidated balance sheet as of January 1, 2019 is as follows: Balance at New Lease Balance at December 31, Standard January 1, 2018 Adjustment 2019 Property, plant and equipment, net $ 598.2 $ (35.2 ) $ 563.0 Other assets 117.4 107.5 224.9 Accounts payable and accrued expenses 725.1 13.6 738.7 Deferred and other long-term liabilities 180.9 41.3 222.2 Deferred income taxes 576.4 4.4 580.8 Retained earnings 3,832.6 13.0 3,845.6 The adoption of the new lease accounting standard did not have a material impact on the Company’s results of operations or cash flows. Recent Accounting Pronouncements Not Yet Adopted There have been no other accounting pronouncements issued but not yet adopted by the Company which are expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows. |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Reconciliation Of Weighted Average Number Of Common Shares Outstanding | . The following table sets forth a reconciliation of the weighted-average number of shares of Common Stock outstanding to the weighted-average number of shares outstanding on a diluted basis: 2021 2020 2019 Weighted average common shares outstanding - basic 244.9 246.8 246.2 Dilutive effect of stock options 4.7 5.4 5.9 Weighted average common shares outstanding - diluted 249.6 252.2 252.1 Antidilutive stock options outstanding 1.6 1.5 1.5 |
Summary of Pre-Tax Expense Associated with Fair value of Unvested Stock Options and Restricted Stock Awards | The following table presents the pre-tax expense associated with the fair value of unvested stock options and restricted stock awards included in SG&A expenses and in cost of sales: For the Year Ended December 31, 2021 2020 2019 Cost of sales $ 3.3 $ 3.6 $ 2.8 Selling, general and administrative expenses 22.3 21.0 19.6 Total $ 25.6 $ 24.6 $ 22.4 |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles | The effects of the recently adopted lease accounting standard to the Company’s consolidated balance sheet as of January 1, 2019 is as follows: Balance at New Lease Balance at December 31, Standard January 1, 2018 Adjustment 2019 Property, plant and equipment, net $ 598.2 $ (35.2 ) $ 563.0 Other assets 117.4 107.5 224.9 Accounts payable and accrued expenses 725.1 13.6 738.7 Deferred and other long-term liabilities 180.9 41.3 222.2 Deferred income taxes 576.4 4.4 580.8 Retained earnings 3,832.6 13.0 3,845.6 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Carrying Amounts and Estimated Fair Values of Other Financial Instruments | The following table presents the carrying amounts and estimated fair values of the Company’s other financial instruments at December 31, 2021 and December 31, 2020: December 31, 2021 December 31, 2020 Input Carrying Fair Carrying Fair Level Amount Value Amount Value Financial Assets: Cash equivalents Level 1 $ 17.1 $ 17.1 $ 73.7 $ 73.7 Financial Liabilities: Short-term borrowings Level 2 252.8 252.8 351.4 351.4 Term loan due May 1, 2022 Level 2 0.0 0.0 300.0 300.0 2.45% Senior notes due August 1, 2022 Level 2 300.0 302.9 299.9 310.1 2.875% Senior notes due October 1, 2022 Level 2 399.9 406.4 399.9 416.6 Term loan due December 22, 2024 Level 2 400.0 400.0 0.0 0.0 3.15% Senior notes due August 1, 2027 Level 2 424.7 450.1 424.7 472.4 2.3% Senior notes due December 15, 2031 Level 2 399.2 403.5 0.0 0.0 3.95% Senior notes due August 1, 2047 Level 2 397.5 471.6 397.4 502.2 Interest Rate Swap Lock Agreement liability Level 2 41.6 41.6 57.0 57.0 Business Acquisition Liabilities Level 3 34.0 34.0 118.0 118.0 |
Derivative Instruments and Ri_2
Derivative Instruments and Risk Management (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Derivative Instruments And Hedging Activities Disclosure [Abstract] | |
Schedule of Notional Amounts | The notional amount of a derivative instrument is the nominal or face amount used to calculate payments made on that instrument. Notional amounts are presented in the following table: Notional Notional Amount Amount December 31, 2021 December 31, 2020 Derivatives designated as hedging instruments Foreign exchange contracts $ 216.3 $ 252.7 Interest rate swap lock $ 300.0 $ 300.0 Diesel fuel contracts 0.0 gallons 6.7 gallons Commodities contracts 72.1 pounds 84.0 pounds Derivatives not designated as hedging instruments Foreign exchange contracts $ 5.9 $ 8.0 Equity derivatives $ 28.9 $ 23.3 |
Inventories (Tables)
Inventories (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Components of Inventories | Inventories consist of the following: December 31, December 31, 2021 2020 Raw materials and supplies $ 116.2 $ 112.9 Work in process 40.0 33.0 Finished goods 379.2 349.5 Total $ 535.4 $ 495.4 |
Property, Plant and Equipment_2
Property, Plant and Equipment, Net ("PP&E") (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Property Plant And Equipment [Abstract] | |
Components of Property, Plant and Equipment | PP&E consist of the following: December 31, December 31, 2021 2020 Land $ 28.3 $ 28.3 Buildings and improvements 290.8 265.3 Machinery and equipment 828.9 793.4 Software 107.8 103.0 Office equipment and other assets 92.7 85.1 Construction in progress 104.3 86.8 Gross PP&E 1,452.8 1,361.9 Less accumulated depreciation and amortization 800.1 749.1 Net PP&E $ 652.7 $ 612.8 For the Year Ended December 31, 2021 2020 2019 Depreciation expense on PP&E $ 68.4 $ 66.2 $ 63.8 |
Acquisitions (Tables)
Acquisitions (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
TheraBreath Acquisition | |
Fair Values of Assets Acquired | The preliminary fair values of the net assets at acquisition are set forth as follows: Accounts receivable $ 11.3 Inventory 12.9 Trade name (indefinite lived) 487.0 Other intangible assets 30.1 Goodwill 43.7 Accounts payable and accrued expenses (15.0 ) Business acquisition liabilities - long-term (14.0 ) Cash purchase price (net of cash acquired) $ 556.0 |
Zicam Acquisition | |
Fair Values of Assets Acquired | The fair values of the net assets acquired are set forth as follows: Inventory and other working capital $ 40.2 Property, plant and equipment 0.5 Trade name 367.8 Other intangible assets 93.8 Goodwill 152.2 Current liabilities (13.1 ) Deferred income taxes (108.0 ) Long-term liabilities (20.7 ) Cash purchase price (net of cash acquired) $ 512.7 |
Flawless Acquisition | |
Fair Values of Assets Acquired | The fair values of the net assets acquired are set forth as follows: Trade name $ 447.3 Other intangible assets 121.8 Goodwill 87.9 Business acquisition liability (182.0 ) Cash purchase price $ 475.0 |
Goodwill and Other Intangible_2
Goodwill and Other Intangibles, Net (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Amortizable Intangible Assets | The following table provides information related to the carrying value of all intangible assets, other than goodwill: December 31, 2021 December 31, 2020 Gross Amortization Gross Carrying Accumulated Period Carrying Accumulated Amount Amortization Net (Years) Amount Amortization Net Amortizable intangible assets: Trade names $ 1,386.7 $ (336.2 ) $ 1,050.5 3-20 $ 1,389.6 $ (269.6 ) $ 1,120.0 Customer Relationships 664.0 (322.4 ) 341.6 15-20 659.5 (291.2 ) 368.3 Patents/Formulas 239.1 (99.4 ) 139.7 4-20 230.5 (85.3 ) 145.2 Total $ 2,289.8 $ (758.0 ) $ 1,531.8 $ 2,279.6 $ (646.1 ) $ 1,633.5 |
Indefinite Lived Intangible Assets | Indefinite lived intangible assets - Carrying value December 31, December 31, 2021 2020 Trade names $ 1,962.5 $ 1,476.7 |
Carrying Amount of Goodwill | The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows: Consumer Consumer Specialty Domestic International Products Total Balance at December 31, 2019 $ 1,707.9 $ 235.6 $ 136.0 $ 2,079.5 PERL WEISS divestiture 0.0 (1.3 ) 0.0 (1.3 ) Zicam acquired goodwill 151.4 0.0 0.0 151.4 Balance at December 31, 2020 $ 1,859.3 $ 234.3 $ 136.0 $ 2,229.6 TheraBreath acquired goodwill 39.3 4.4 0.0 43.7 Tax related and other 1.2 0.0 0.0 1.2 Balance at December 31, 2021 $ 1,899.8 $ 238.7 $ 136.0 $ 2,274.5 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Leases [Abstract] | |
Summary of Lease Information | A summary of the Company’s lease information is as follows: December 31, December 31, Classification 2021 2020 Assets Right of use assets Other Assets $ 159.4 $ 181.6 Liabilities Current lease liabilities Accounts Payable and Accrued Expenses $ 24.4 $ 25.0 Long-term lease liabilities Deferred and Other Long-term Liabilities 146.6 168.3 Total lease liabilities $ 171.0 $ 193.3 Other information Weighted-average remaining lease term (years) 9.1 9.7 Weighted-average discount rate 4.3 % 4.3 % Twelve Months Twelve Months Twelve Months Ended Ended Ended December 31, 2021 December 31, 2020 December 31, 2019 Statement of Income Lease cost (1) $ 32.7 $ 27.7 $ 24.6 Twelve Months Twelve Months Ended Ended December 31, 2021 December 31, 2020 Other information Leased assets obtained in exchange for new lease liabilities (2) $ 3.5 $ 50.4 Cash paid for amounts included in the measurement of lease liabilities $ 32.6 $ 25.6 (1) Lease expense is included in cost of sales or SG&A expenses based on the nature of the leased item. Short-term lease expense is excluded from this amount and is not material. The Company also has certain variable leases which are not material. The noncash component of lease expense for the twelve months ended December 31, 2021, 2020 and 2019 was $25.4, $20.1 and $17.9, respectively, is included in the amortization caption in the condensed consolidated statement of cash flows. (2) Leased assets obtained in exchange for new lease liabilities in 2021 primarily consisted of equipment lease additions, partially offset by lease modification terminations. Leased assets obtained in exchange for new lease liabilities in 2020 consisted of $32.4 of real estate lease additions and $18.0 of equipment lease additions, net of modifications. These additions included $24.1 for an agreement between the Company and a third-party warehouse provider for warehouse space and equipment. |
Summary of Minimum Annual Rentals Including Reasonably Assured Renewal Options under Lease Agreements | The Company’s minimum annual rentals including reasonably assured renewal options under lease agreements are as follows: Operating Leases 2022 $ 30.9 2023 26.6 2024 24.2 2025 22.7 2026 15.3 2027 and thereafter 91.0 Total future minimum lease commitments 210.7 Less: Imputed Interest (39.7 ) Present value of lease liabilities $ 171.0 |
Accounts Payable and Accrued _2
Accounts Payable and Accrued Expenses (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Payables And Accruals [Abstract] | |
Accounts Payable and Accrued Expenses | Accounts payable and accrued expenses consist of the following: December 31, December 31, 2021 2020 Trade accounts payable $ 663.8 $ 588.1 Accrued marketing and promotion costs 201.6 177.8 Accrued wages and related benefit costs 87.7 124.2 Other accrued current liabilities 166.6 134.4 Total $ 1,119.7 $ 1,024.5 |
Short-Term Borrowings and Lon_2
Short-Term Borrowings and Long-Term Debt (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Components of Short-Term Borrowings and Long-Term Debt | Short-term borrowings and long-term debt consist of the following: December 31, December 31, 2021 2020 Short-term borrowings Commercial paper issuances $ 249.7 $ 349.0 Various debt due to international banks 3.1 2.4 Total short-term borrowings $ 252.8 $ 351.4 Long-term debt Term loan due May 1, 2022 $ 0.0 $ 300.0 2.45% Senior notes due August 1, 2022 300.0 300.0 Less: Discount 0.0 (0.1 ) 2.875% Senior notes due October 1, 2022 400.0 400.0 Less: Discount (0.1 ) (0.1 ) Term loan due December 22, 2024 400.0 0.0 3.15% Senior notes due August 1, 2027 425.0 425.0 Less: Discount (0.3 ) (0.3 ) 2.3% Senior notes due December 15, 2031 400.0 0.0 Less: Discount (0.8 ) 0.0 3.95% Senior notes due August 1, 2047 400.0 400.0 Less: Discount (2.5 ) (2.6 ) Debt issuance costs, net (11.2 ) (9.4 ) Total long-term debt 2,310.1 1,812.5 Less: current maturities (699.4 ) 0.0 Net long-term debt $ 1,610.7 $ 1,812.5 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Components of Income Before Taxes | The components of income before taxes are as follows: 2021 2020 2019 Domestic $ 958.6 $ 921.6 $ 726.7 Foreign 73.1 52.2 47.0 Total $ 1,031.7 $ 973.8 $ 773.7 |
Schedule of U.S. Federal, State and Foreign Income Taxes | The following table summarizes the provision for U.S. federal, state and foreign income taxes: 2021 2020 2019 Current: U.S. federal $ 130.6 $ 114.2 $ 117.2 State 34.1 32.1 24.9 Foreign 19.2 15.9 10.1 183.9 162.2 152.2 Deferred: U.S. federal 16.5 22.9 3.6 State 4.5 4.2 (0.5 ) Foreign (0.7 ) (1.4 ) 2.5 20.3 25.7 5.6 Total provision $ 204.2 $ 187.9 $ 157.8 |
Components of Deferred Tax Assets and Liabilities | Deferred tax assets (liabilities) consist of the following at December 31: 2021 2020 Deferred tax assets: Accounts receivable $ 8.6 $ 6.8 Deferred compensation 52.0 48.6 Pension, postretirement and postemployment benefits 6.1 6.3 Other 23.3 19.9 Tax credit carryforwards/other tax attributes 2.9 17.9 International operating loss carryforwards 8.2 8.7 Interest rate swaps 10.3 14.2 Total gross deferred tax assets 111.4 122.4 Valuation allowances (13.1 ) (22.6 ) Total deferred tax assets 98.3 99.8 Deferred tax liabilities: Goodwill (270.2 ) (226.9 ) Trade names and other intangibles (508.5 ) (520.4 ) Property, plant and equipment (55.5 ) (56.1 ) Total deferred tax liabilities (834.2 ) (803.4 ) Net deferred tax liability $ (735.9 ) $ (703.6 ) Long term net deferred tax asset 9.2 3.7 Long term net deferred tax liability (745.1 ) (707.3 ) Net deferred tax liability $ (735.9 ) $ (703.6 ) |
Effective Tax Rate Reconciliation | The difference between tax expense and the tax that would result from the application of the federal statutory rate is as follows: 2021 2020 2019 Statutory rate 21 % 21 % 21 % Tax that would result from use of the federal statutory rate $ 216.6 $ 204.5 $ 162.4 State and local income tax, net of federal effect 30.5 28.7 19.3 Varying tax rates of foreign affiliates 2.6 2.8 1.8 Valuation Allowances (8.5 ) 2.9 0.9 Stock Options Exercised (29.0 ) (29.4 ) (16.1 ) Worthless Stock Deduction - Investment in Brazil 0.0 0.0 (12.0 ) Reserve for Uncertain Tax Position - Investment in Brazil 0.0 (10.6 ) 12.0 Other (8.0 ) (11.0 ) (10.5 ) Recorded tax expense $ 204.2 $ 187.9 $ 157.8 Effective tax rate 19.8 % 19.3 % 20.4 % |
Reconciliation of Unrecognized Tax Benefits | A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: 2021 2020 2019 Unrecognized tax benefits at January 1 $ 7.3 $ 18.9 $ 4.7 Gross increases - tax positions in current period 0.3 0.0 13.2 Gross increases - tax positions in prior period 0.8 1.6 1.4 Gross decreases - tax positions in prior period 0.0 (11.8 ) 0.0 Decreases due to settlements and payments 0.0 (1.4 ) 0.0 Lapse of statute of limitations (3.7 ) 0.0 (0.4 ) Unrecognized tax benefits at December 31 $ 4.7 $ 7.3 $ 18.9 |
Stock Based Compensation Plan_2
Stock Based Compensation Plans and Other Benefit Plans (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Summary of Option Activity | Stock option transactions for the year ended December 31, 2021 were as follows: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Price Term Value Outstanding as of December 31, 2020 12.7 $ 50.72 Granted 1.5 84.71 Exercised (2.8 ) 35.48 Cancelled (0.1 ) 75.48 Outstanding as of December 31, 2021 11.3 $ 58.83 6.1 $ 493.3 Exercisable as of December 31, 2021 6.7 $ 44.80 4.3 $ 380.5 |
Summary of Information Relating to Options Outstanding and Exercisable | The following table summarizes information relating to options outstanding and exercisable as of December 31, 2021: Options Outstanding Options Exercisable Weighted Weighted Weighted Outstanding Average Average Exercisable Average Range of as of Remaining Exercise as of Exercise Exercise Prices 12/31/2021 Contractual Price 12/31/2021 Price $20.01 - $30.00 0.2 0.5 $ 26.98 0.2 $ 26.98 $30.01 - $40.00 1.3 2.2 $ 33.93 1.3 $ 33.93 $40.01 - $50.00 2.4 3.9 $ 44.07 2.4 $ 44.07 $50.01 - $60.00 2.7 6.0 $ 51.98 2.7 $ 51.98 $60.01 - $70.00 0.1 6.9 $ 65.52 0.1 $ 65.52 $70.01 - $80.00 3.1 8.0 $ 75.36 0.0 $ - $80.01 - $90.00 1.5 9.5 $ 84.70 0.0 $ - 11.3 6.1 $ 58.83 6.7 $ 44.80 |
Information Regarding Intrinsic Value of Stock Options Exercised and Stock Compensation Expense Related to Stock Option Awards | The following table provides information regarding the intrinsic value of stock options exercised and stock compensation expense related to stock option awards: 2021 2020 2019 Intrinsic Value of Stock Options Exercised $ 157.3 $ 159.8 $ 93.1 Stock Compensation Expense Related to Stock Option Awards $ 23.3 $ 21.1 $ 20.3 Issued Stock Options 1.5 1.9 1.5 Weighted Average Fair Value of Stock Options issued (per share) $ 17.32 $ 12.85 $ 14.90 Fair Value of Stock Options Issued $ 26.6 $ 24.5 $ 22.1 |
Assumptions Used in Valuation of Issued Stock Options | The following table provides a summary of the assumptions used in the valuation of issued stock options: 2021 2020 2019 Risk-free interest rate 1.3 % 0.5 % 2.0 % Expected life in years 7.2 7.3 7.3 Expected volatility 20.7 % 19.9 % 17.2 % Dividend yield 1.2 % 1.3 % 1.2 % |
Accumulated Other Comprehensi_2
Accumulated Other Comprehensive Income (Loss) (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Components of Changes in Accumulated Other Comprehensive Income (Loss) | The components of changes in accumulated other comprehensive income (“AOCI”) are as follows: Accumulated Foreign Defined Other Currency Benefit Derivative Comprehensive Adjustments Plans Agreements Income (Loss) Balance December 31, 2018 $ (42.5 ) $ 0.9 $ (12.0 ) $ (53.6 ) Other comprehensive income before reclassifications 3.8 (1.3 ) (30.2 ) (27.7 ) Amounts reclassified to consolidated statement of income (a) 1.9 0.0 6.1 8.0 Tax benefit (expense) 0.0 0.4 6.2 6.6 Other comprehensive income (loss) 5.7 (0.9 ) (17.9 ) (13.1 ) Balance December 31, 2019 $ (36.8 ) $ 0.0 $ (29.9 ) $ (66.7 ) Other comprehensive income (loss) before reclassifications 10.4 0.0 (34.8 ) (24.4 ) Amounts reclassified to consolidated statement of income (a) 0.0 0.0 5.8 5.8 Tax benefit (expense) 0.0 0.0 7.7 7.7 Other comprehensive income (loss) 10.4 0.0 (21.3 ) (10.9 ) Balance December 31, 2020 $ (26.4 ) $ 0.0 $ (51.2 ) $ (77.6 ) Other comprehensive income (loss) before reclassifications (3.8 ) (0.8 ) 26.7 22.1 Amounts reclassified to consolidated statement of income (a) 0.0 0.0 (8.2 ) (8.2 ) Tax benefit (expense) 0.0 0.2 (4.7 ) (4.5 ) Other comprehensive income (loss) (3.8 ) (0.6 ) 13.8 9.4 Balance December 31, 2021 $ (30.2 ) $ (0.6 ) $ (37.4 ) $ (68.2 ) ( a ) Amounts reclassified to cost of sales, selling, general and administrative expenses, or interest expense. |
Related Party Transactions (Tab
Related Party Transactions (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
Schedule of Related Party Transactions | The following summarizes the balances and transactions between the Company and each of Armand and ArmaKleen, in which the Company holds a 50% Armand ArmaKleen Year Ended December 31, Year Ended December 31, 2021 2020 2019 2021 2020 2019 Purchases by Company $ 12.9 $ 14.2 $ 14.3 $ 0.0 $ 0.0 $ 0.0 Sales by Company $ 0.0 $ 0.0 $ 0.0 $ 1.2 $ 1.1 $ 1.1 Outstanding Accounts Receivable $ 1.0 $ 0.7 $ 0.6 $ 0.9 $ 0.5 $ 0.8 Outstanding Accounts Payable $ 1.2 $ 1.4 $ 1.6 $ 0.0 $ 0.0 $ 0.0 Administration & Management Oversight Services (1) $ 2.2 $ 2.1 $ 2.7 $ 2.1 $ 2.2 $ 2.1 (1) Billed by Company and recorded as a reduction of SG&A expenses. |
Segments (Tables)
Segments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Segment Reporting [Abstract] | |
Selected Financial Information Relating To Company's Segments | The following table presents selected financial information relating to the Company’s segments for each of the three years in the period ended December 31, 2021: Consumer Consumer Domestic International SPD Corporate (1) As Net sales 2021 $ 3,941.9 $ 912.2 $ 336.0 $ 0.0 $ 5,190.1 2020 3,767.6 828.2 300.0 0.0 4,895.8 2019 3,302.6 756.3 298.8 0.0 4,357.7 Gross profit 2021 1,795.8 402.1 112.7 (47.1 ) 2,263.5 2020 1,801.1 368.8 104.1 (59.8 ) 2,214.2 2019 1,575.2 346.1 110.9 (48.2 ) 1,984.0 Marketing Expenses 2021 442.1 131.1 4.5 0.0 577.7 2020 460.6 126.9 3.7 0.0 591.2 2019 398.0 112.9 4.1 0.0 515.0 Selling, General and Administrative Expenses 2021 445.3 135.7 72.8 (47.1 ) 606.7 2020 455.6 128.7 68.8 (59.8 ) 593.3 2019 470.1 151.7 55.2 (48.2 ) 628.8 Income from Operations 2021 908.4 135.3 35.4 0.0 1,079.1 2020 884.9 113.2 31.6 0.0 1,029.7 2019 707.1 81.5 51.6 0.0 840.2 Equity in Earnings of Affiliates 2021 0.0 0.0 0.0 9.4 9.4 2020 0.0 0.0 0.0 6.7 6.7 2019 0.0 0.0 0.0 6.6 6.6 Income Before Income Taxes 2021 861.4 127.3 33.6 9.4 1,031.7 2020 832.4 105.0 29.7 6.7 973.8 2019 645.8 74.0 47.3 6.6 773.7 Identifiable Assets 2021 6,354.5 1,192.9 332.7 116.4 7,996.5 2020 5,819.8 1,144.5 339.7 110.5 7,414.5 2019 5,099.1 1,110.0 340.4 107.9 6,657.4 Capital Expenditures 2021 100.3 8.4 10.1 0.0 118.8 2020 81.8 7.1 10.0 0.0 98.9 2019 53.9 9.4 10.4 0.0 73.7 Depreciation & Amortization 2021 170.0 31.1 15.4 2.6 219.1 2020 142.8 29.6 14.5 2.8 189.7 2019 131.9 27.1 14.1 3.3 176.4 (1) Corporate reflects the following: (A) (B) (C) |
Product Line Revenues From External Customers | Product line revenues from external customers for each of the three years ended December 31, 2021, December 31, 2020 and December 31, 2019 were as follows: 2021 2020 2019 Household Products $ 2,103.0 $ 2,038.5 $ 1,821.7 Personal Care Products 1,838.9 1,729.1 1,480.9 Total Consumer Domestic 3,941.9 3,767.6 3,302.6 Total Consumer International 912.2 828.2 756.3 Total SPD 336.0 300.0 298.8 Total Consolidated Net Sales $ 5,190.1 $ 4,895.8 $ 4,357.7 |
Significant Accounting Polici_4
Significant Accounting Policies - Additional Information (Details) $ in Millions | 12 Months Ended | ||||
Dec. 31, 2021USD ($)Segment | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Jan. 01, 2019USD ($) | Dec. 31, 2018USD ($) | |
Significant Accounting Policies [Line Items] | |||||
Number of reportable segments | Segment | 3 | ||||
Number of product | 3 | ||||
Proceed from sale of accounts receivable | $ 21.2 | $ 21.1 | $ 26 | ||
Adjustments to reflect inventory at net realizable value | 36.2 | 17 | |||
Research and development expenses | 105.2 | 102.6 | 93.6 | ||
Operating lease, right of use assets | 159.4 | 181.6 | $ 107 | $ 55 | |
Operating lease, liability | 171 | 193.3 | 109 | 57 | |
Deferred rent | 2 | ||||
Property, Plant and Equipment, Net | 652.7 | 612.8 | 598.2 | 563 | |
Deferred Income Taxes | 745.1 | 707.3 | 576.4 | 580.8 | |
Retained earnings | $ 5,366 | $ 4,786 | $ 3,832.6 | 3,845.6 | |
Cease-use liability | 7 | ||||
Accounting Standards Update 2016-02 | |||||
Significant Accounting Policies [Line Items] | |||||
Operating lease, right of use assets | 52 | ||||
Property, Plant and Equipment, Net | (35.2) | 35 | |||
Deferred Income Taxes | 4.4 | 4 | |||
Retained earnings | $ 13 | $ 13 | |||
Minimum | |||||
Significant Accounting Policies [Line Items] | |||||
Intangible assets, estimated useful life (years) | 3 years | ||||
Minimum | Building and Building Improvements | |||||
Significant Accounting Policies [Line Items] | |||||
Property, plant and equipment, useful life | 9 years | ||||
Minimum | Machinery and Equipment | |||||
Significant Accounting Policies [Line Items] | |||||
Property, plant and equipment, useful life | 3 years | ||||
Minimum | Office Equipment | |||||
Significant Accounting Policies [Line Items] | |||||
Property, plant and equipment, useful life | 3 years | ||||
Maximum | |||||
Significant Accounting Policies [Line Items] | |||||
Intangible assets, estimated useful life (years) | 20 years | ||||
Maximum | Software | |||||
Significant Accounting Policies [Line Items] | |||||
Intangible assets, estimated useful life (years) | 10 years | ||||
Maximum | Building and Building Improvements | |||||
Significant Accounting Policies [Line Items] | |||||
Property, plant and equipment, useful life | 40 years | ||||
Maximum | Machinery and Equipment | |||||
Significant Accounting Policies [Line Items] | |||||
Property, plant and equipment, useful life | 20 years | ||||
Maximum | Office Equipment | |||||
Significant Accounting Policies [Line Items] | |||||
Property, plant and equipment, useful life | 10 years | ||||
Armand Products Company | |||||
Significant Accounting Policies [Line Items] | |||||
Percentage of ownership interest | 50.00% | 50.00% | 50.00% | ||
ArmaKleen Company | |||||
Significant Accounting Policies [Line Items] | |||||
Percentage of ownership interest | 50.00% | 50.00% | 50.00% |
Reconciliation of Weighted Aver
Reconciliation of Weighted Average Number of Shares of Common Stock Outstanding (Details) - shares shares in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Earnings Per Share [Abstract] | |||
Weighted average shares outstanding - Basic | 244.9 | 246.8 | 246.2 |
Dilutive effect of stock options | 4.7 | 5.4 | 5.9 |
Weighted average common shares outstanding - diluted | 249.6 | 252.2 | 252.1 |
Antidilutive stock options outstanding | 1.6 | 1.5 | 1.5 |
Summary of Pre-Tax Expense Asso
Summary of Pre-Tax Expense Associated with Fair value of Unvested Stock Options and Restricted Stock Awards (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | |||
Stock compensation expense | $ 23.3 | $ 21.1 | $ 20.3 |
Cost of Sales | |||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | |||
Stock compensation expense | 3.3 | 3.6 | 2.8 |
Selling, General and Administrative Expenses | |||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | |||
Stock compensation expense | 22.3 | 21 | 19.6 |
Unvested Stock Options Fair Value | |||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | |||
Stock compensation expense | $ 25.6 | $ 24.6 | $ 22.4 |
Summary of Adjustments to Balan
Summary of Adjustments to Balance Sheet due to Adoption of Guidance (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 | Dec. 31, 2018 |
New Accounting Pronouncements Or Change In Accounting Principle [Line Items] | |||||
Property, Plant and Equipment, Net | $ 652.7 | $ 612.8 | $ 598.2 | $ 563 | |
Other Assets | 332.5 | 340.4 | 117.4 | 224.9 | |
Accounts payable and accrued expenses | 1,119.7 | 1,024.5 | 725.1 | 738.7 | |
Deferred and Other Long-term Liabilities | 298.3 | 367.7 | 180.9 | 222.2 | |
Deferred Income Taxes | 745.1 | 707.3 | 576.4 | 580.8 | |
Retained earnings | $ 5,366 | $ 4,786 | $ 3,832.6 | 3,845.6 | |
ASU 2016-02 | |||||
New Accounting Pronouncements Or Change In Accounting Principle [Line Items] | |||||
Property, Plant and Equipment, Net | (35.2) | $ 35 | |||
Other Assets | 107.5 | ||||
Accounts payable and accrued expenses | 13.6 | ||||
Deferred and Other Long-term Liabilities | 41.3 | ||||
Deferred Income Taxes | 4.4 | 4 | |||
Retained earnings | $ 13 | $ 13 |
Carrying Amounts and Estimated
Carrying Amounts and Estimated Fair Values of Other Financial Instruments (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Short-term borrowings | $ 252.8 | $ 351.4 |
Senior Notes | 2,310.1 | 1,812.5 |
Carrying Amount | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents | 17.1 | 73.7 |
Short-term borrowings | 252.8 | 351.4 |
Business Acquisition Liabilities | 34 | 118 |
Fair Value | Fair Value, Inputs, Level 1 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents | 17.1 | 73.7 |
Fair Value | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Short-term borrowings | 252.8 | 351.4 |
Fair Value | Fair Value, Inputs, Level 3 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Business Acquisition Liabilities | 34 | 118 |
Interest Rate Swap | Carrying Amount | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest Rate Swap Lock Agreement liability | 41.6 | 57 |
Interest Rate Swap | Fair Value | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest Rate Swap Lock Agreement liability | 41.6 | 57 |
Term Loan Due May 1, 2022 | Carrying Amount | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Term loan | 0 | 300 |
Term Loan Due May 1, 2022 | Fair Value | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Term loan | 0 | 300 |
2.45% Senior notes due August 1, 2022 | Carrying Amount | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Senior Notes | 300 | 299.9 |
2.45% Senior notes due August 1, 2022 | Fair Value | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Senior notes | 302.9 | 310.1 |
2.875% Senior notes due October 1, 2022 | Carrying Amount | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Senior Notes | 399.9 | 399.9 |
2.875% Senior notes due October 1, 2022 | Fair Value | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Senior notes | 406.4 | 416.6 |
2.3% Senior notes due December 15, 2031 | Carrying Amount | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Senior Notes | 399.2 | 0 |
2.3% Senior notes due December 15, 2031 | Fair Value | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Senior notes | 403.5 | 0 |
Term loan due December 22, 2024 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Term loan | 400 | 0 |
Term loan due December 22, 2024 | Carrying Amount | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Term loan | 400 | 0 |
Term loan due December 22, 2024 | Fair Value | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Term loan | 400 | 0 |
3.95% Senior notes due August 1, 2047 | Carrying Amount | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Senior Notes | 397.5 | 397.4 |
3.95% Senior notes due August 1, 2047 | Fair Value | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Senior notes | 471.6 | 502.2 |
3.15% Senior notes due August 1, 2027 | Carrying Amount | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Senior Notes | 424.7 | 424.7 |
3.15% Senior notes due August 1, 2027 | Fair Value | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Senior notes | $ 450.1 | $ 472.4 |
Carrying Amounts and Estimate_2
Carrying Amounts and Estimated Fair Values of Other Financial Instruments (Parenthetical) (Details) | Dec. 31, 2021 | Dec. 31, 2020 |
2.45% Senior notes due August 1, 2022 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest rate of debt | 2.45% | 2.45% |
2.45% Senior notes due August 1, 2022 | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest rate of debt | 2.45% | 2.45% |
2.875% Senior notes due October 1, 2022 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest rate of debt | 2.875% | 2.875% |
2.875% Senior notes due October 1, 2022 | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest rate of debt | 2.875% | 2.875% |
3.15% Senior notes due August 1, 2027 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest rate of debt | 3.15% | 3.15% |
3.15% Senior notes due August 1, 2027 | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest rate of debt | 3.15% | 3.15% |
2.3% Senior notes due December 15, 2031 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest rate of debt | 2.30% | 2.30% |
2.3% Senior notes due December 15, 2031 | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest rate of debt | 2.30% | 2.30% |
3.95% Senior notes due August 1, 2047 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest rate of debt | 3.95% | 3.95% |
3.95% Senior notes due August 1, 2047 | Fair Value, Inputs, Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Interest rate of debt | 3.95% | 3.95% |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | 32 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | May 01, 2019 | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Decrease In Interest Rate Swap Lock Agreements Liability | $ 15.4 | $ 15.4 | ||
Zicam Acquisition | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Business Acquisition Liabilities | $ 20 | 20 | $ 20 | |
Business Acquisition Payable Period | 5 years | |||
TheraBreath Acquisition | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Business Acquisition Liabilities | $ 14 | 14 | ||
TheraBreath Acquisition | Minimum | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Business Acquisition Payable Period | 2 years | |||
TheraBreath Acquisition | Maximum | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Business Acquisition Payable Period | 4 years | |||
Flawless Acquisition | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Business Acquisition Liabilities | $ 0 | 0 | 98 | $ 182 |
Increase (decrease) in estimate of contingent consideration liability | (98) | (182) | ||
Designated as Hedging Instrument | Interest Rate Swap Lock | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Notional amount | $ 300 | $ 300 | $ 300 |
Derivative Instruments and Ri_3
Derivative Instruments and Risk Management - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Face value of unexpired foreign currency contracts | $ 222.2 | |
Foreign Exchange Contract | ||
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Face value of unexpired foreign currency contracts | $ 216.3 | |
Designated as Hedging Instrument | ||
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Derivative hedging agreements covering diesel fuel requirements | 75.00% | |
Designated as Hedging Instrument | Foreign Exchange Contract | ||
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Notional amount | $ 216.3 | $ 252.7 |
Designated as Hedging Instrument | Interest Rate Swap Lock | ||
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Notional amount | $ 300 | $ 300 |
Schedule of Notional Amounts (D
Schedule of Notional Amounts (Details) lb in Millions, gal in Millions, $ in Millions | Dec. 31, 2021USD ($)gallb | Dec. 31, 2020USD ($)gallb |
Designated as Hedging Instrument | Foreign Exchange Contract | ||
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Derivatives, Notional Amount | $ 216.3 | $ 252.7 |
Designated as Hedging Instrument | Interest Rate Swap Lock | ||
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Derivatives, Notional Amount | $ 300 | $ 300 |
Designated as Hedging Instrument | Diesel fuel contracts | ||
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Derivatives, Notional Amount, Volume | gal | 0 | 6.7 |
Designated as Hedging Instrument | Commodities Contracts | ||
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Derivatives, Notional Amount, Volume | lb | 72.1 | 84 |
Not Designated as Hedging Instrument | Foreign Exchange Contract | ||
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Derivatives, Notional Amount | $ 5.9 | $ 8 |
Not Designated as Hedging Instrument | Equity derivatives | ||
Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||
Derivatives, Notional Amount | $ 28.9 | $ 23.3 |
Components of Inventories (Deta
Components of Inventories (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Inventory, Finished Goods and Work in Process, Net of Reserves [Abstract] | ||
Raw materials and supplies | $ 116.2 | $ 112.9 |
Work in process | 40 | 33 |
Finished goods | 379.2 | 349.5 |
Total | $ 535.4 | $ 495.4 |
Components of Property, Plant a
Components of Property, Plant and Equipment (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 |
Property, Plant and Equipment [Line Items] | ||||
Gross PP&E | $ 1,452.8 | $ 1,361.9 | ||
Less accumulated depreciation and amortization | 800.1 | 749.1 | ||
Net PP&E | 652.7 | 612.8 | $ 598.2 | $ 563 |
Land | ||||
Property, Plant and Equipment [Line Items] | ||||
Gross PP&E | 28.3 | 28.3 | ||
Building and Building Improvements | ||||
Property, Plant and Equipment [Line Items] | ||||
Gross PP&E | 290.8 | 265.3 | ||
Machinery and Equipment | ||||
Property, Plant and Equipment [Line Items] | ||||
Gross PP&E | 828.9 | 793.4 | ||
Software | ||||
Property, Plant and Equipment [Line Items] | ||||
Gross PP&E | 107.8 | 103 | ||
Office equipment and other assets | ||||
Property, Plant and Equipment [Line Items] | ||||
Gross PP&E | 92.7 | 85.1 | ||
Construction in progress | ||||
Property, Plant and Equipment [Line Items] | ||||
Gross PP&E | $ 104.3 | $ 86.8 |
Depreciation and Interest Charg
Depreciation and Interest Charges on Property, Plant and Equipment (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Property Plant And Equipment [Abstract] | |||
Depreciation expense | $ 68.4 | $ 66.2 | $ 63.8 |
Acquisitions - Additional Infor
Acquisitions - Additional Information (Details) - USD ($) $ in Millions | Dec. 24, 2021 | May 01, 2019 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 10, 2021 | Dec. 01, 2020 | Mar. 08, 2018 |
Business Acquisition [Line Items] | |||||||||
Net Sales | $ 5,190.1 | $ 4,895.8 | $ 4,357.7 | ||||||
TheraBreath Acquisition | |||||||||
Business Acquisition [Line Items] | |||||||||
Closing payment of net of cash acquired | $ 556 | ||||||||
Additional cash payment | 14 | 14 | |||||||
Net Sales | 100 | ||||||||
Proceeds from term loan for business acquisition | $ 400 | ||||||||
Financing term loan period | 3 years | ||||||||
Underwritten public offering senior notes | $ 400 | ||||||||
Business Acquisition Liabilities | $ 14 | ||||||||
TheraBreath Acquisition | Minimum | |||||||||
Business Acquisition [Line Items] | |||||||||
Business acquisition, period | 2 years | 2 years | |||||||
Average life of the amortizable intangible assets, years | 10 years | ||||||||
TheraBreath Acquisition | Maximum | |||||||||
Business Acquisition [Line Items] | |||||||||
Business acquisition, period | 4 years | 4 years | |||||||
Average life of the amortizable intangible assets, years | 20 years | ||||||||
Zicam Acquisition | |||||||||
Business Acquisition [Line Items] | |||||||||
Closing payment of net of cash acquired | $ 512.7 | 512.7 | $ 512.7 | ||||||
Additional cash payment | $ 20 | $ 20 | |||||||
Business acquisition, period | 5 years | 5 years | |||||||
Net Sales | 107 | ||||||||
Business Acquisition Liabilities | $ 20 | $ 20 | 20 | ||||||
Zicam Acquisition | Minimum | |||||||||
Business Acquisition [Line Items] | |||||||||
Average life of the amortizable intangible assets, years | 10 years | ||||||||
Zicam Acquisition | Maximum | |||||||||
Business Acquisition [Line Items] | |||||||||
Average life of the amortizable intangible assets, years | 20 years | ||||||||
Flawless Acquisition | |||||||||
Business Acquisition [Line Items] | |||||||||
Closing payment of net of cash acquired | $ 475 | ||||||||
Purchase price paid at closing | $ 475 | ||||||||
Commercial paper borrowings and loan term | 3 years | ||||||||
Business Acquisition Liabilities | $ 182 | $ 98 | $ 0 | $ 98 | |||||
Net sales target period | 12 months | ||||||||
Net sales target ending date | Dec. 31, 2021 | ||||||||
Flawless Acquisition | Minimum | |||||||||
Business Acquisition [Line Items] | |||||||||
Average life of the amortizable intangible assets, years | 15 years | ||||||||
Flawless Acquisition | Maximum | |||||||||
Business Acquisition [Line Items] | |||||||||
Average life of the amortizable intangible assets, years | 20 years | ||||||||
Passport Food Safety Solutions, Inc. | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition Liabilities | $ 7.3 |
Fair Values of Net Assets Acqui
Fair Values of Net Assets Acquired (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 24, 2021 | Dec. 31, 2020 | Dec. 01, 2020 | Dec. 31, 2019 | May 01, 2019 |
Business Acquisition [Line Items] | ||||||
Goodwill | $ 2,274.5 | $ 2,229.6 | $ 2,079.5 | |||
Long-term liabilities | $ (20.7) | |||||
TheraBreath Acquisition | ||||||
Business Acquisition [Line Items] | ||||||
Accounts receivable | $ 11.3 | |||||
Inventory | 12.9 | |||||
Trade name (indefinite lived) | 487 | |||||
Other intangible assets | 30.1 | |||||
Goodwill | 43.7 | |||||
Business acquisition liability | (14) | |||||
Accounts payable and accrued expenses | (15) | |||||
Business acquisition liabilities - long-term | (14) | |||||
Cash purchase price (net of cash acquired) | $ 556 | |||||
Zicam Acquisition | ||||||
Business Acquisition [Line Items] | ||||||
Inventory and other working capital | 40.2 | |||||
Property, plant and equipment | 0.5 | |||||
Trade name (indefinite lived) | 367.8 | |||||
Other intangible assets | 93.8 | |||||
Goodwill | 152.2 | |||||
Current liabilities | (13.1) | |||||
Deferred income taxes | (108) | |||||
Business acquisition liability | (20) | (20) | ||||
Cash purchase price (net of cash acquired) | 512.7 | $ 512.7 | ||||
Flawless Acquisition | ||||||
Business Acquisition [Line Items] | ||||||
Trade name (indefinite lived) | $ 447.3 | |||||
Other intangible assets | 121.8 | |||||
Goodwill | 87.9 | |||||
Business acquisition liability | $ 0 | $ (98) | (182) | |||
Cash purchase price (net of cash acquired) | $ 475 |
Amortizable Intangible Assets (
Amortizable Intangible Assets (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Finite-Lived Intangible Assets [Line Items] | ||
December 31, 2021 | $ 2,289.8 | $ 2,279.6 |
December 31, 2021 | (758) | (646.1) |
December 31, 2021 | $ 1,531.8 | 1,633.5 |
Minimum | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 3 years | |
Maximum | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 20 years | |
Trade Names | ||
Finite-Lived Intangible Assets [Line Items] | ||
December 31, 2021 | $ 1,386.7 | 1,389.6 |
December 31, 2021 | (336.2) | (269.6) |
December 31, 2021 | $ 1,050.5 | 1,120 |
Trade Names | Minimum | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 3 years | |
Trade Names | Maximum | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 20 years | |
Customer Relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
December 31, 2021 | $ 664 | 659.5 |
December 31, 2021 | (322.4) | (291.2) |
December 31, 2021 | $ 341.6 | 368.3 |
Customer Relationships | Minimum | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 15 years | |
Customer Relationships | Maximum | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 20 years | |
Patents | ||
Finite-Lived Intangible Assets [Line Items] | ||
December 31, 2021 | $ 239.1 | 230.5 |
December 31, 2021 | (99.4) | (85.3) |
December 31, 2021 | $ 139.7 | $ 145.2 |
Patents | Minimum | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 4 years | |
Patents | Maximum | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 20 years |
Indefinite Lived Intangible Ass
Indefinite Lived Intangible Assets (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Trade Names | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Gross Carrying Value, Trade names | $ 1,962.5 | $ 1,476.7 |
Goodwill and Other Intangible_3
Goodwill and Other Intangibles, Net - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
Amortization expense of intangible assets | $ 120.3 | $ 99.9 | $ 90.4 | |
Estimated amortization expense, 2022 | 117 | |||
December 31, 2021 | $ 2,289.8 | 2,279.6 | ||
Percent of fair value in excess of carrying value | 70.00% | |||
Average royalty rate | 10.00% | |||
Net book value | $ 1,531.8 | 1,633.5 | ||
Proceeds from sale of assets | 0 | 7 | 0 | |
Gain on sale of business | 0 | 3 | $ 0 | |
PERL WEISS Toothpaste | ||||
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
Goodwill | $ 1.3 | |||
Proceeds from sale of assets | 7 | |||
PERL WEISS Toothpaste | Selling, General and Administrative Expenses | ||||
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
Gain on sale of business | 3 | |||
Trojan Trade Name | ||||
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
December 31, 2021 | 176.4 | |||
Trade Name And Other Intangible Assets | ||||
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
Carrying value of assets | 11.3 | |||
Net book value | $ 9.5 | |||
Remaining amortization period | 7 years | |||
Trade Names | ||||
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
December 31, 2021 | 1,386.7 | $ 1,389.6 | ||
Net book value | $ 1,050.5 | $ 1,120 | ||
Trade Names | PERL WEISS Toothpaste | ||||
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
Net book value of trade name | $ 2.7 | |||
UNITED STATES | ||||
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
Fair value assumptions discount rate | 7.00% | |||
International | ||||
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
Fair value assumptions discount rate | 8.50% | |||
Maximum | ||||
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
Estimated amortization expense, 2023 | $ 115 | |||
Estimated amortization expense, 2024 | 115 | |||
Estimated amortization expense, 2025 | 115 | |||
Estimated amortization expense, 2026 | 115 | |||
Estimated amortization expense, 2027 | 115 | |||
Minimum | ||||
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||
Estimated amortization expense, 2023 | 107 | |||
Estimated amortization expense, 2024 | 107 | |||
Estimated amortization expense, 2025 | 107 | |||
Estimated amortization expense, 2026 | 107 | |||
Estimated amortization expense, 2027 | $ 107 |
Carrying Amount of Goodwill (De
Carrying Amount of Goodwill (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Goodwill [Line Items] | ||
Beginning balance | $ 2,229.6 | $ 2,079.5 |
Tax related and other | 1.2 | |
Ending balance | 2,274.5 | 2,229.6 |
PERL WEISS Toothpaste | ||
Goodwill [Line Items] | ||
PERL WEISS divestiture | (1.3) | |
TheraBreath Acquisition | ||
Goodwill [Line Items] | ||
Goodwill acquired during the period | 43.7 | |
Zicam Acquisition | ||
Goodwill [Line Items] | ||
Goodwill acquired during the period | 151.4 | |
Consumer Domestic | ||
Goodwill [Line Items] | ||
Beginning balance | 1,859.3 | 1,707.9 |
Tax related and other | 1.2 | |
Ending balance | 1,899.8 | 1,859.3 |
Consumer Domestic | PERL WEISS Toothpaste | ||
Goodwill [Line Items] | ||
PERL WEISS divestiture | 0 | |
Consumer Domestic | TheraBreath Acquisition | ||
Goodwill [Line Items] | ||
Goodwill acquired during the period | 39.3 | |
Consumer Domestic | Zicam Acquisition | ||
Goodwill [Line Items] | ||
Goodwill acquired during the period | 151.4 | |
Consumer International | ||
Goodwill [Line Items] | ||
Beginning balance | 234.3 | 235.6 |
Tax related and other | 0 | |
Ending balance | 238.7 | 234.3 |
Consumer International | PERL WEISS Toothpaste | ||
Goodwill [Line Items] | ||
PERL WEISS divestiture | (1.3) | |
Consumer International | TheraBreath Acquisition | ||
Goodwill [Line Items] | ||
Goodwill acquired during the period | 4.4 | |
Consumer International | Zicam Acquisition | ||
Goodwill [Line Items] | ||
Goodwill acquired during the period | 0 | |
Specialty Products | ||
Goodwill [Line Items] | ||
Beginning balance | 136 | 136 |
Tax related and other | 0 | |
Ending balance | 136 | 136 |
Specialty Products | PERL WEISS Toothpaste | ||
Goodwill [Line Items] | ||
PERL WEISS divestiture | 0 | |
Specialty Products | TheraBreath Acquisition | ||
Goodwill [Line Items] | ||
Goodwill acquired during the period | $ 0 | |
Specialty Products | Zicam Acquisition | ||
Goodwill [Line Items] | ||
Goodwill acquired during the period | $ 0 |
Summary of Lease information (D
Summary of Lease information (Details) - USD ($) $ in Millions | 12 Months Ended | |||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 | Dec. 31, 2018 | ||
Leases [Abstract] | ||||||
Right of use assets | $ 159.4 | $ 181.6 | $ 107 | $ 55 | ||
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] | Other current assets | Other current assets | ||||
Current lease liabilities | $ 24.4 | $ 25 | ||||
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] | Accounts payable and accrued expenses | Accounts payable and accrued expenses | ||||
Long-term lease liabilities | $ 146.6 | $ 168.3 | ||||
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] | Deferred and Other Long-term Liabilities | Deferred and Other Long-term Liabilities | ||||
Total lease liabilities | $ 171 | $ 193.3 | $ 109 | $ 57 | ||
Weighted-average remaining lease term (years) | 9 years 1 month 6 days | 9 years 8 months 12 days | ||||
Weighted-average discount rate | 4.30% | 4.30% | ||||
Lease cost | [1] | $ 32.7 | $ 27.7 | $ 24.6 | ||
Leased assets obtained in exchange for new lease liabilities | [2] | 3.5 | 50.4 | |||
Cash paid for amounts included in the measurement of lease liabilities | $ 32.6 | $ 25.6 | ||||
[1] | Lease expense is included in cost of sales or SG&A expenses based on the nature of the leased item. Short-term lease expense is excluded from this amount and is not material. The Company also has certain variable leases which are not material. The noncash component of lease expense for the twelve months ended December 31, 2021, 2020 and 2019 was $25.4, $20.1 and $17.9, respectively, is included in the amortization caption in the condensed consolidated statement of cash flows. | |||||
[2] | Leased assets obtained in exchange for new lease liabilities in 2021 primarily consisted of equipment lease additions, partially offset by lease modification terminations. Leased assets obtained in exchange for new lease liabilities in 2020 consisted of $32.4 of real estate lease additions and $18.0 of equipment lease additions, net of modifications. These additions included $24.1 for an agreement between the Company and a third-party warehouse provider for warehouse space and equipment. |
Summary of Lease information (P
Summary of Lease information (Parenthetical) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Leases [Abstract] | |||
Noncash component of lease expense | $ 25.4 | $ 20.1 | $ 17.9 |
Leased asset obtained in exchange for operating lease liability real estate and modification | 32.4 | ||
Lease liability agreement with third-party | 24.1 | ||
Equipment lease addition | $ 18 |
Summary of Minimum Annual Renta
Summary of Minimum Annual Rentals Including Reasonably Assured Renewal Options under Lease Agreements (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Jan. 01, 2019 | Dec. 31, 2018 |
Operating Leases | ||||
2022 | $ 30.9 | |||
2023 | 26.6 | |||
2024 | 24.2 | |||
2025 | 22.7 | |||
2026 | 15.3 | |||
2027 and thereafter | 91 | |||
Total future minimum lease commitments | 210.7 | |||
Less: Imputed Interest | (39.7) | |||
Present value of lease liabilities | $ 171 | $ 193.3 | $ 109 | $ 57 |
Accounts Payable and Accrued _3
Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 |
Accounts Payable and Accrued Liabilities, Current [Abstract] | ||||
Trade accounts payable | $ 663.8 | $ 588.1 | ||
Accrued marketing and promotion costs | 201.6 | 177.8 | ||
Accrued wages and related benefit costs | 87.7 | 124.2 | ||
Other accrued current liabilities | 166.6 | 134.4 | ||
Total | $ 1,119.7 | $ 1,024.5 | $ 725.1 | $ 738.7 |
Summary of Short-Term Borrowing
Summary of Short-Term Borrowings and Long-Term Debt (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Short-term borrowings | ||
Commercial paper issuances | $ 249.7 | $ 349 |
Various debt due to international banks | 3.1 | 2.4 |
Total short-term borrowings | 252.8 | 351.4 |
Long-term debt | ||
Debt issuance costs, net | (11.2) | (9.4) |
Total long-term debt | 2,310.1 | 1,812.5 |
Less: current maturities | (699.4) | 0 |
Net long-term debt | 1,610.7 | 1,812.5 |
2.45% Senior notes due August 1, 2022 | ||
Long-term debt | ||
Underwritten public offering senior notes | 300 | 300 |
Less: Discount | 0 | (0.1) |
2.875% Senior notes due October 1, 2022 | ||
Long-term debt | ||
Underwritten public offering senior notes | 400 | 400 |
Less: Discount | (0.1) | (0.1) |
Term Loan | ||
Long-term debt | ||
Term loan | 0 | 300 |
Term loan | 0 | 300 |
2.3% Senior notes due December 15, 2031 | ||
Long-term debt | ||
Underwritten public offering senior notes | 400 | 0 |
Less: Discount | (0.8) | 0 |
Term loan due December 22, 2024 | ||
Long-term debt | ||
Term loan | 400 | 0 |
Term loan | 400 | 0 |
3.95% Senior notes due August 1, 2047 | ||
Long-term debt | ||
Underwritten public offering senior notes | 400 | 400 |
Less: Discount | (2.5) | (2.6) |
3.15% Senior notes due August 1, 2027 | ||
Long-term debt | ||
Underwritten public offering senior notes | 425 | 425 |
Less: Discount | $ (0.3) | $ (0.3) |
Summary of Short-Term Borrowi_2
Summary of Short-Term Borrowings and Long-Term Debt (Parenthetical) (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
2.45% Senior notes due August 1, 2022 | ||
Debt Instrument [Line Items] | ||
Interest rate of debt | 2.45% | 2.45% |
Maturity date of debt | Aug. 1, 2022 | Aug. 1, 2022 |
2.875% Senior notes due October 1, 2022 | ||
Debt Instrument [Line Items] | ||
Interest rate of debt | 2.875% | 2.875% |
Maturity date of debt | Oct. 1, 2022 | Oct. 1, 2022 |
3.15% Senior notes due August 1, 2027 | ||
Debt Instrument [Line Items] | ||
Interest rate of debt | 3.15% | 3.15% |
Maturity date of debt | Aug. 1, 2027 | Aug. 1, 2027 |
2.3% Senior notes due December 15, 2031 | ||
Debt Instrument [Line Items] | ||
Interest rate of debt | 2.30% | 2.30% |
Maturity date of debt | Dec. 15, 2031 | Dec. 15, 2031 |
3.95% Senior notes due August 1, 2047 | ||
Debt Instrument [Line Items] | ||
Interest rate of debt | 3.95% | 3.95% |
Maturity date of debt | Aug. 1, 2047 | Aug. 1, 2047 |
Short-Term Borrowings and Lon_3
Short-Term Borrowings and Long-Term Debt - Additional Information (Details) - USD ($) $ in Millions | Dec. 22, 2021 | May 01, 2019 | Jan. 25, 2019 | Jul. 25, 2017 | Sep. 26, 2012 | Jul. 31, 2021 | Jun. 30, 2021 | May 31, 2020 | Sep. 30, 2011 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 15, 2031 | Mar. 31, 2020 |
Debt Instrument [Line Items] | |||||||||||||||
Maximum leverage ratio related to material acquisition | 4.25 | 4.25 | |||||||||||||
Maximum leverage ratio related to additional material acquisition | 4.25 | 4.25 | |||||||||||||
Repayments of long-term debt | $ 300 | $ 0 | $ 600 | ||||||||||||
Commercial paper issuances | 249.7 | $ 349 | |||||||||||||
Interest Rate Swap | Designated as Hedging Instrument | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Derivatives, Notional Amount | $ 300 | ||||||||||||||
2.45% Senior notes due August 1, 2022 | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Maturity date of debt | Aug. 1, 2022 | Aug. 1, 2022 | |||||||||||||
Interest rate of debt | 2.45% | 2.45% | |||||||||||||
3.15% Senior notes due August 1, 2027 | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Maturity date of debt | Aug. 1, 2027 | Aug. 1, 2027 | |||||||||||||
Interest rate of debt | 3.15% | 3.15% | |||||||||||||
3.95% Senior notes due August 1, 2047 | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Maturity date of debt | Aug. 1, 2047 | Aug. 1, 2047 | |||||||||||||
Interest rate of debt | 3.95% | 3.95% | |||||||||||||
Term Loan | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Maturity date of debt | May 1, 2022 | ||||||||||||||
Term loan | $ 0 | $ 300 | |||||||||||||
Repayments of long-term debt | $ 200 | $ 100 | |||||||||||||
2.3% Senior Notes | TheraBreath | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Proceeds from long term borrowing | $ 400 | ||||||||||||||
2.3% Senior Notes | Floating Rate Senior Notes due 2031 | TheraBreath | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Interest rate of debt | 2.30% | ||||||||||||||
$1.425 M Senior Notes | Water Pik Inc | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Proceeds from long term borrowing | 1,425 | ||||||||||||||
Repayments of long-term debt | $ 300 | ||||||||||||||
Floating rate senior notes, description | three-month U.S. Dollar LIBOR plus 0.15% | ||||||||||||||
Repayments of debt | 200 | ||||||||||||||
$1.425 M Senior Notes | Floating Rate Senior notes due January 25, 2019 | Water Pik Inc | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Term loan | 300 | ||||||||||||||
$1.425 M Senior Notes | 2.45% Senior notes due August 1, 2022 | Water Pik Inc | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Term loan | $ 300 | ||||||||||||||
Interest rate of debt | 2.45% | ||||||||||||||
$1.425 M Senior Notes | 3.15% Senior notes due August 1, 2027 | Water Pik Inc | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Term loan | $ 425 | ||||||||||||||
Interest rate of debt | 3.15% | ||||||||||||||
$1.425 M Senior Notes | 3.95% Senior notes due August 1, 2047 | Water Pik Inc | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Term loan | $ 400 | ||||||||||||||
Interest rate of debt | 3.95% | ||||||||||||||
2.875% Senior notes due October 1, 2022 | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Maturity date of debt | Oct. 1, 2022 | ||||||||||||||
Term loan | $ 400 | ||||||||||||||
Interest rate of debt | 2.875% | ||||||||||||||
Interest payment frequency | payable semi-annually, on each April 1 and October 1 | ||||||||||||||
Federal Funds Rate | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 0.50% | ||||||||||||||
LIBOR-Based Rate | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 1.00% | ||||||||||||||
LIBOR-Based Rate | $1.425 M Senior Notes | Water Pik Inc | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 0.15% | ||||||||||||||
Minimum | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Customary fees, including commitment fee | 0.07% | ||||||||||||||
Minimum | LIBOR-Based Rate | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 0.875% | ||||||||||||||
Minimum | Base Rate | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 0.00% | ||||||||||||||
Maximum | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Customary fees, including commitment fee | 0.175% | ||||||||||||||
Consolidated funded indebtedness to EBITDA ratio | 3.75 | 3.75 | |||||||||||||
Maximum | LIBOR-Based Rate | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 1.50% | ||||||||||||||
Maximum | Base Rate | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 0.50% | ||||||||||||||
Commercial Paper | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Maximum borrowing capacity | $ 1,000 | $ 1,000 | |||||||||||||
Amount borrowed under unsecured revolving credit facility | $ 746 | ||||||||||||||
Weighted average interest rate | 0.30% | 0.26% | |||||||||||||
Notes maximum maturity days | 397 days | ||||||||||||||
New Unsecured Revolving Credit Facility | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Additional borrowing capacity | $ 600 | ||||||||||||||
Maturity date of debt | Mar. 29, 2024 | ||||||||||||||
Unsecured Revolving Credit Facility | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Maximum borrowing capacity | $ 1,000 | ||||||||||||||
Maturity date of debt | Mar. 29, 2023 | ||||||||||||||
Amount borrowed under unsecured revolving credit facility | $ 825 | ||||||||||||||
Repayment of unsecured revolving credit facility | $ 825 | ||||||||||||||
Term Loan | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Maturity date of debt | Dec. 22, 2024 | ||||||||||||||
Term loan | $ 400 | ||||||||||||||
Term Loan | Minimum | LIBOR-Based Rate | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 0.60% | ||||||||||||||
Term Loan | Maximum | LIBOR-Based Rate | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 1.25% | ||||||||||||||
Term Loan | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Maturity date of debt | May 1, 2019 | ||||||||||||||
Term loan | $ 300 | ||||||||||||||
Term Loan | Minimum | LIBOR-Based Rate | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 0.60% | ||||||||||||||
Term Loan | Maximum | LIBOR-Based Rate | |||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||
Debt instrument, variable interest rate | 1.25% |
Components of Income Before Tax
Components of Income Before Taxes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |||
Domestic | $ 958.6 | $ 921.6 | $ 726.7 |
Foreign | 73.1 | 52.2 | 47 |
Income before Income Taxes | $ 1,031.7 | $ 973.8 | $ 773.7 |
Schedule of U.S. Federal, State
Schedule of U.S. Federal, State and Foreign Income Taxes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |||
U.S. federal | $ 130.6 | $ 114.2 | $ 117.2 |
State, Current | 34.1 | 32.1 | 24.9 |
Foreign, Current | 19.2 | 15.9 | 10.1 |
Current income tax expense (benefit) | 183.9 | 162.2 | 152.2 |
U.S. federal, Deferred | 16.5 | 22.9 | 3.6 |
State, Deferred | 4.5 | 4.2 | (0.5) |
Foreign, Deferred | (0.7) | (1.4) | 2.5 |
Deferred income tax expense (benefit) | 20.3 | 25.7 | 5.6 |
Recorded tax expense | $ 204.2 | $ 187.9 | $ 157.8 |
Components of Deferred Tax Asse
Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 |
Income Tax Disclosure [Abstract] | ||||
Accounts receivable | $ 8.6 | $ 6.8 | ||
Deferred compensation | 52 | 48.6 | ||
Pension, postretirement and postemployment benefits | 6.1 | 6.3 | ||
Other | 23.3 | 19.9 | ||
Tax credit carryforwards/other tax attributes | 2.9 | 17.9 | ||
International operating loss carryforwards | 8.2 | 8.7 | ||
Interest rate swaps | 10.3 | 14.2 | ||
Total gross deferred tax assets | 111.4 | 122.4 | ||
Valuation allowances | (13.1) | (22.6) | ||
Total deferred tax assets | 98.3 | 99.8 | ||
Goodwill | (270.2) | (226.9) | ||
Trade names and other intangibles | (508.5) | (520.4) | ||
Property, plant and equipment | (55.5) | (56.1) | ||
Total deferred tax liabilities | (834.2) | (803.4) | ||
Net deferred tax liability | (735.9) | (703.6) | ||
Long term net deferred tax asset | 9.2 | 3.7 | ||
Long term net deferred tax liability | $ (745.1) | $ (707.3) | $ (576.4) | $ (580.8) |
Effective Tax Rate Reconciliati
Effective Tax Rate Reconciliation (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |||
Statutory rate | 21.00% | 21.00% | 21.00% |
Tax that would result from use of the federal statutory rate | $ 216.6 | $ 204.5 | $ 162.4 |
State and local income tax, net of federal effect | 30.5 | 28.7 | 19.3 |
Varying tax rates of foreign affiliates | 2.6 | 2.8 | 1.8 |
Valuation Allowances | (8.5) | 2.9 | 0.9 |
Stock Options Exercised | (29) | (29.4) | (16.1) |
Worthless Stock Deduction - Investment in Brazil | 0 | 0 | (12) |
Reserve for Uncertain Tax Position - Investment in Brazil | 0 | (10.6) | 12 |
Other | (8) | (11) | (10.5) |
Recorded tax expense | $ 204.2 | $ 187.9 | $ 157.8 |
Effective tax rate | 19.80% | 19.30% | 20.40% |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Tax [Line Items] | ||||
Valuation allowance | $ 8.1 | $ 8.7 | ||
Deferred tax assets, valuation allowances | 13.1 | 22.6 | ||
Reserve for uncertain tax position relating to worthless stock deduction for investment | 0 | (10.6) | $ 12 | |
Decrease in unrecognized tax benefits is reasonably possible | 0.7 | 12 | ||
Effective Income tax rate reconciliation, tax settlement, amount | 1.4 | |||
Income tax benefits recognized from deductions | 10.6 | |||
Uncertain tax positions that would affect the effective tax rate | 4.1 | 6.2 | 18 | |
Uncertain tax positions that would result in adjustments to deferred taxes | 0.6 | 1.1 | 0.9 | |
Interest expense associated with uncertain tax positions | 0.5 | 0.4 | 0.4 | |
Unrecognized tax benefits, accrued interest expense | 0.5 | 1 | 0.6 | |
Brazil | ||||
Income Tax [Line Items] | ||||
Reserve for uncertain tax position relating to worthless stock deduction for investment | 12 | |||
Quimica Geral Do Nordeste Sa | ||||
Income Tax [Line Items] | ||||
Deferred tax assets, valuation allowances | 0.9 | 1.3 | ||
Foreign Tax Authority | ||||
Income Tax [Line Items] | ||||
Loss carryforward | 25.1 | |||
Foreign Tax Authority | Unrealized Foreign Tax Credit Carryforwards | ||||
Income Tax [Line Items] | ||||
Deferred tax assets, valuation allowances | $ 4.1 | 12.6 | ||
Deferred Tax Assets, Tax Credit Carryforwards, Foreign | 8.5 | $ 8.5 | $ 8.5 | |
Foreign Tax Authority | Unrealized Foreign Tax Credit Carryforwards | Internal Revenue Service (IRS) | ||||
Income Tax [Line Items] | ||||
Deferred Tax Assets, Tax Credit Total Value, Foreign | 6.5 | |||
Deferred Tax Assets, Tax Credit Utilized, Foreign | $ 2 |
Reconciliation of Unrecognized
Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |||
Unrecognized tax benefits at January 1 | $ 7.3 | $ 18.9 | $ 4.7 |
Gross increases - tax positions in current period | 0.3 | 0 | 13.2 |
Gross increases - tax positions in prior period | 0.8 | 1.6 | 1.4 |
Gross decreases - tax positions in prior period | 0 | (11.8) | 0 |
Decreases due to settlements and payments | 0 | (1.4) | 0 |
Lapse of statute of limitations | (3.7) | 0 | (0.4) |
Unrecognized tax benefits at December 31 | $ 4.7 | $ 7.3 | $ 18.9 |
Stock Based Compensation Plan_3
Stock Based Compensation Plans and Other Benefit Plans - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Compensation cost not yet recognized | $ 19 | ||
Period of amortization expected to be recognized | 3 years | ||
Non-cash compensation expense | $ 23.7 | $ 21.5 | $ 20.8 |
Restricted shares, stock compensation expense | $ 1.9 | 3.1 | 1.5 |
Percentage of incentive bonus contribution | 85.00% | ||
Deferred Compensation Plans | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Stock compensation, liability | $ 131.9 | 116.9 | |
Amounts charged to earnings | $ 2.2 | 2.1 | $ 1 |
Shares held in rabbi trust | 149,000 | ||
Deferred Compensation Plans | Other Assets | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Funded balances | $ 107.3 | 101.4 | |
Deferred Compensation Plans | Management | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Percentage of compensation contribution | 85.00% | ||
Deferred Compensation Plans | Director | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Percentage of compensation contribution | 100.00% | ||
Exercise Options Granted Between Two Thousand Seven Through Two Thousand Seventeen Within Three Year From Date Of Termination | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Minimum required participant age and years of service | 65 years | ||
Stock Option | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Stock exercise period, years | 10 years | ||
Vesting period | 3 years | ||
Minimum service period, years | 5 years | ||
Minimum required participant age with five years of service | 55 years | ||
Restricted Shares | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Stock compensation, liability | $ 1.9 | $ 0 |
Summary of Option Activity (Det
Summary of Option Activity (Details) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended |
Dec. 31, 2021USD ($)$ / sharesshares | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Beginning Balance, Options | shares | 12.7 |
Granted, Options | shares | 1.5 |
Exercised, Options | shares | (2.8) |
Cancelled, Options | shares | (0.1) |
Ending Balance, Options | shares | 11.3 |
Exercisable as of December 31, 2021, Options | shares | 6.7 |
Beginning Balance, Weighted-Average Exercise Price | $ / shares | $ 50.72 |
Granted, Weighted-Average Exercise Price | $ / shares | 84.71 |
Exercised, Weighted-Average Exercise Price | $ / shares | 35.48 |
Cancelled, Weighted-Average Exercise Price | $ / shares | 75.48 |
Ending Balance, Weighted-Average Exercise Price | $ / shares | 58.83 |
Exercisable as of December 31, 2021, Weighted-Average Exercise Price | $ / shares | $ 44.80 |
Outstanding as of December 31, 2021, Weighted-Average Remaining Contractual Term, years | 6 years 1 month 6 days |
Exercisable as of December 31, 2021, Weighted-Average Remaining Contractual Term, years | 4 years 3 months 18 days |
Outstanding as of December 31, 2021, Aggregate Intrinsic Value | $ | $ 493.3 |
Exercisable as of December 31, 2021, Aggregate Intrinsic Value | $ | $ 380.5 |
Summary of Information Relating
Summary of Information Relating to Options Outstanding and Exercisable (Details) - $ / shares shares in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Outstanding as of 12/31/2021 | 11.3 | |
Weighted Average Remaining Contractual Life | 6 years 1 month 6 days | |
Options Outstanding Weighted-Average Exercise Price | $ 58.83 | $ 50.72 |
Exercisable as of 12/31/2021 | 6.7 | |
Options Exercisable Weighted-Average Exercise Price | $ 44.80 | |
$20.01 - $30.00 | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Range of Exercise Prices, Lower Limit | 20.01 | |
Range of Exercise Prices, Upper Limit | $ 30 | |
Outstanding as of 12/31/2021 | 0.2 | |
Weighted Average Remaining Contractual Life | 6 months | |
Options Outstanding Weighted-Average Exercise Price | $ 26.98 | |
Exercisable as of 12/31/2021 | 0.2 | |
Options Exercisable Weighted-Average Exercise Price | $ 26.98 | |
$30.01 - $40.00 | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Range of Exercise Prices, Lower Limit | 30.01 | |
Range of Exercise Prices, Upper Limit | $ 40 | |
Outstanding as of 12/31/2021 | 1.3 | |
Weighted Average Remaining Contractual Life | 2 years 2 months 12 days | |
Options Outstanding Weighted-Average Exercise Price | $ 33.93 | |
Exercisable as of 12/31/2021 | 1.3 | |
Options Exercisable Weighted-Average Exercise Price | $ 33.93 | |
$40.01 - $50.00 | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Range of Exercise Prices, Lower Limit | 40.01 | |
Range of Exercise Prices, Upper Limit | $ 50 | |
Outstanding as of 12/31/2021 | 2.4 | |
Weighted Average Remaining Contractual Life | 3 years 10 months 24 days | |
Options Outstanding Weighted-Average Exercise Price | $ 44.07 | |
Exercisable as of 12/31/2021 | 2.4 | |
Options Exercisable Weighted-Average Exercise Price | $ 44.07 | |
$50.01 - $60.00 | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Range of Exercise Prices, Lower Limit | 50.01 | |
Range of Exercise Prices, Upper Limit | $ 60 | |
Outstanding as of 12/31/2021 | 2.7 | |
Weighted Average Remaining Contractual Life | 6 years | |
Options Outstanding Weighted-Average Exercise Price | $ 51.98 | |
Exercisable as of 12/31/2021 | 2.7 | |
Options Exercisable Weighted-Average Exercise Price | $ 51.98 | |
$60.01 - $70.00 | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Range of Exercise Prices, Lower Limit | 60.01 | |
Range of Exercise Prices, Upper Limit | $ 70 | |
Outstanding as of 12/31/2021 | 0.1 | |
Weighted Average Remaining Contractual Life | 6 years 10 months 24 days | |
Options Outstanding Weighted-Average Exercise Price | $ 65.52 | |
Exercisable as of 12/31/2021 | 0.1 | |
Options Exercisable Weighted-Average Exercise Price | $ 65.52 | |
$70.01 - $80.00 | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Range of Exercise Prices, Lower Limit | 70.01 | |
Range of Exercise Prices, Upper Limit | $ 80 | |
Outstanding as of 12/31/2021 | 3.1 | |
Weighted Average Remaining Contractual Life | 8 years | |
Options Outstanding Weighted-Average Exercise Price | $ 75.36 | |
Exercisable as of 12/31/2021 | 0 | |
$80.01 - $90.00 | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Range of Exercise Prices, Lower Limit | $ 80.01 | |
Range of Exercise Prices, Upper Limit | $ 90 | |
Outstanding as of 12/31/2021 | 1.5 | |
Weighted Average Remaining Contractual Life | 9 years 6 months | |
Options Outstanding Weighted-Average Exercise Price | $ 84.70 | |
Exercisable as of 12/31/2021 | 0 |
Schedule of Share Based Compens
Schedule of Share Based Compensation Stock Options (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |||
Intrinsic Value of Stock Options Exercised | $ 157.3 | $ 159.8 | $ 93.1 |
Stock Compensation Expense Related to Stock Option Awards | $ 23.3 | $ 21.1 | $ 20.3 |
Issued Stock Options | 1.5 | 1.9 | 1.5 |
Weighted Average Fair Value of Stock Options issued (per share) | $ 17.32 | $ 12.85 | $ 14.90 |
Fair Value of Stock Options Issued | $ 26.6 | $ 24.5 | $ 22.1 |
Assumptions Used in Valuation o
Assumptions Used in Valuation of Issued Stock Options (Details) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |||
Risk-free interest rate | 1.30% | 0.50% | 2.00% |
Expected life in years | 7 years 2 months 12 days | 7 years 3 months 18 days | 7 years 3 months 18 days |
Expected volatility | 20.70% | 19.90% | 17.20% |
Dividend yield | 1.20% | 1.30% | 1.20% |
Share Repurchases - Additional
Share Repurchases - Additional Information (Details) - USD ($) shares in Millions, $ in Millions | 1 Months Ended | 12 Months Ended | |||||||
Feb. 28, 2022 | Dec. 31, 2021 | Feb. 28, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Oct. 28, 2021 | Nov. 01, 2017 | |
Accelerated Share Repurchases [Line Items] | |||||||||
Stock repurchase program, authorized amount | $ 1,000 | $ 500 | |||||||
Payment for share repurchase | $ 500 | $ 300 | $ 250 | ||||||
Commercial Bank | |||||||||
Accelerated Share Repurchases [Line Items] | |||||||||
Stock repurchase program, authorized amount | $ 180 | 180 | |||||||
Accelerated share repurchases, settlement payment | $ 200 | 200 | |||||||
Accelerated share repurchases received | 0.2 | 1.8 | |||||||
Stock repurchase program remaining authorized repurchase amount | $ 729.7 | $ 729.7 | |||||||
Commercial Bank | |||||||||
Accelerated Share Repurchases [Line Items] | |||||||||
Stock repurchase program, authorized amount | $ 270 | 270 | |||||||
Accelerated share repurchases, settlement payment | $ 300 | $ 300 | |||||||
Accelerated share repurchases received | 0.4 | 3.1 | |||||||
Evergreen Program | |||||||||
Accelerated Share Repurchases [Line Items] | |||||||||
Accelerated share repurchases received | 3.5 | ||||||||
Payment for share repurchase | $ 100 | ||||||||
Repurchase Program | |||||||||
Accelerated Share Repurchases [Line Items] | |||||||||
Accelerated share repurchases received | 2 | ||||||||
Open market share repurchase | 1.8 | ||||||||
Open market share repurchase amount | $ 170.3 | ||||||||
Payment for share repurchase | $ 70.3 |
Components of Changes in Accumu
Components of Changes in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Beginning balance | $ (77.6) | $ (66.7) | $ (53.6) | |
Other comprehensive income (loss) before reclassifications | 22.1 | (24.4) | (27.7) | |
Amounts reclassified to consolidated statement of income | [1] | (8.2) | 5.8 | 8 |
Tax benefit (expense) | (4.5) | 7.7 | 6.6 | |
Other comprehensive income (loss) | 9.4 | (10.9) | (13.1) | |
Ending balance | (68.2) | (77.6) | (66.7) | |
Foreign Currency Adjustments | ||||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Beginning balance | (26.4) | (36.8) | (42.5) | |
Other comprehensive income (loss) before reclassifications | (3.8) | 10.4 | 3.8 | |
Amounts reclassified to consolidated statement of income | [1] | 0 | 0 | 1.9 |
Tax benefit (expense) | 0 | 0 | 0 | |
Other comprehensive income (loss) | (3.8) | 10.4 | 5.7 | |
Ending balance | (30.2) | (26.4) | (36.8) | |
Defined Benefit Plans | ||||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Beginning balance | 0 | 0 | 0.9 | |
Other comprehensive income (loss) before reclassifications | (0.8) | 0 | (1.3) | |
Amounts reclassified to consolidated statement of income | [1] | 0 | 0 | 0 |
Tax benefit (expense) | 0.2 | 0 | 0.4 | |
Other comprehensive income (loss) | (0.6) | 0 | (0.9) | |
Ending balance | (0.6) | 0 | 0 | |
Derivative Agreements | ||||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Beginning balance | (51.2) | (29.9) | (12) | |
Other comprehensive income (loss) before reclassifications | 26.7 | (34.8) | (30.2) | |
Amounts reclassified to consolidated statement of income | [1] | (8.2) | 5.8 | 6.1 |
Tax benefit (expense) | (4.7) | 7.7 | 6.2 | |
Other comprehensive income (loss) | 13.8 | (21.3) | (17.9) | |
Ending balance | $ (37.4) | $ (51.2) | $ (29.9) | |
[1] | Amounts reclassified to cost of sales, selling, general and administrative expenses, or interest expense. |
Commitments, Contingencies an_2
Commitments, Contingencies and Guarantees - Additional Information (Details) $ in Millions | Dec. 24, 2021USD ($) | Apr. 30, 2020USD ($) | May 01, 2019USD ($) | Mar. 08, 2018USD ($) | Jan. 17, 2017USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2021USD ($)T | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2021USD ($) | Jun. 30, 2019USD ($) |
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Annual purchase commitment, in tons | T | 240,000 | ||||||||||
Commitments | $ 362.6 | ||||||||||
Outstanding guarantees and letters of credit | 4.7 | $ 4.7 | |||||||||
Payment of contingent consideration | $ 0 | $ 14.5 | $ 0 | ||||||||
Agro Bio Sciences Inc | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Payment year of achieving certain operating performance | 2019 | ||||||||||
Payment to be made if certain operating performance is achieved | $ 17.8 | ||||||||||
Passport Food Safety Solutions, Inc. | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Payment year of achieving certain operating performance | 2020 | ||||||||||
Payment to be made if certain operating performance is achieved | $ 7.3 | ||||||||||
Flawless Acquisition | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Payment year of achieving certain operating performance | 2021 | ||||||||||
Payment to be made if certain operating performance is achieved | $ 182 | $ 98 | $ 0 | 98 | 0 | ||||||
Increase (decrease) in estimate of contingent consideration liability | (98) | (182) | |||||||||
Zicam Acquisition | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Payment to be made if certain operating performance is achieved | 20 | 20 | 20 | 20 | |||||||
Additional cash payment | $ 20 | $ 20 | |||||||||
Business acquisition, period | 5 years | 5 years | |||||||||
TheraBreath Acquisition | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Payment to be made if certain operating performance is achieved | $ 14 | $ 14 | |||||||||
Additional cash payment | $ 14 | 14 | |||||||||
Maximum | Agro Bio Sciences Inc | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Additional earn-out payment | $ 25 | ||||||||||
Maximum | Passport Food Safety Solutions, Inc. | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Additional earn-out payment | $ 25 | ||||||||||
Maximum | Flawless Acquisition | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Additional earn-out payment | $ 425 | ||||||||||
Maximum | TheraBreath Acquisition | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Business acquisition, period | 4 years | 4 years | |||||||||
Minimum | Agro Bio Sciences Inc | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Payment of contingent consideration | $ 14.5 | ||||||||||
Minimum | TheraBreath Acquisition | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Business acquisition, period | 2 years | 2 years | |||||||||
Updated Sales Forecasts | Agro Bio Sciences Inc | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Payment to be made if certain operating performance is achieved | $ 14.2 | ||||||||||
Updated Sales Forecasts | Passport Food Safety Solutions, Inc. | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Reversed contingent liability | $ 7.3 | ||||||||||
Updated Sales Forecasts | Flawless Acquisition | |||||||||||
Commitments And Contingencies Disclosure [Line Items] | |||||||||||
Increase (decrease) in estimate of contingent consideration liability | $ (94) | $ (98) |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Details) | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Armand Products Company | |||
Related Party Transaction [Line Items] | |||
Percentage of ownership interest | 50.00% | 50.00% | 50.00% |
ArmaKleen Company | |||
Related Party Transaction [Line Items] | |||
Percentage of ownership interest | 50.00% | 50.00% | 50.00% |
Balance and Transactions Betwee
Balance and Transactions Between Company and Related Party (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Armand Products Company | ||||
Related Party Transaction [Line Items] | ||||
Purchases by Company | $ 12.9 | $ 14.2 | $ 14.3 | |
Sales by Company | 0 | 0 | 0 | |
Outstanding Accounts Receivable | 1 | 0.7 | 0.6 | |
Outstanding Accounts Payable | 1.2 | 1.4 | 1.6 | |
Administration & Management Oversight Services | [1] | 2.2 | 2.1 | 2.7 |
ArmaKleen Company | ||||
Related Party Transaction [Line Items] | ||||
Purchases by Company | 0 | 0 | 0 | |
Sales by Company | 1.2 | 1.1 | 1.1 | |
Outstanding Accounts Receivable | 0.9 | 0.5 | 0.8 | |
Outstanding Accounts Payable | 0 | 0 | 0 | |
Administration & Management Oversight Services | [1] | $ 2.1 | $ 2.2 | $ 2.1 |
[1] | Billed by Company and recorded as a reduction of SG&A expenses. |
Segments - Additional Informati
Segments - Additional Information (Details) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021USD ($)Segment | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | |
Segment Reporting Information [Line Items] | |||
Number of reportable segments | Segment | 3 | ||
Equity in earnings of affiliates | $ 9.4 | $ 6.7 | $ 6.6 |
Net Sales | $ 5,190.1 | $ 4,895.8 | $ 4,357.7 |
Geographic Concentration Risk | Sales Revenue, Goods, Net | Major Customer | |||
Segment Reporting Information [Line Items] | |||
Concentration risk, percentage | 5.00% | ||
Geographic Concentration Risk | Long Lived Assets | Major Customer | |||
Segment Reporting Information [Line Items] | |||
Concentration risk, percentage | 5.00% | ||
Customer Concentration Risk | Sales Revenue, Goods, Net | Major Customers Group | |||
Segment Reporting Information [Line Items] | |||
Concentration risk, percentage | 37.00% | 36.00% | 36.00% |
Customer Concentration Risk | Sales Revenue, Goods, Net | Wal-Mart Stores Inc And Affiliates | |||
Segment Reporting Information [Line Items] | |||
Concentration risk, percentage | 24.00% | 23.00% | 24.00% |
Customer name | Walmart Inc. and its affiliates | ||
UNITED STATES | Geographic Concentration Risk | Sales Revenue, Goods, Net | |||
Segment Reporting Information [Line Items] | |||
Concentration risk, percentage | 82.00% | 83.00% | 82.00% |
UNITED STATES | Geographic Concentration Risk | Long Lived Assets | |||
Segment Reporting Information [Line Items] | |||
Concentration risk, percentage | 96.00% | 96.00% | 95.00% |
Intersegment Eliminations | |||
Segment Reporting Information [Line Items] | |||
Net Sales | $ 10.8 | $ 11.7 | $ 10.5 |
Armand Products Company | |||
Segment Reporting Information [Line Items] | |||
Percentage of ownership interest | 50.00% | 50.00% | 50.00% |
Armand Products Company and ArmaKleen Company | |||
Segment Reporting Information [Line Items] | |||
Equity in earnings of affiliates | $ 9.4 | $ 6.7 | $ 6.6 |
ArmaKleen Company | |||
Segment Reporting Information [Line Items] | |||
Percentage of ownership interest | 50.00% | 50.00% | 50.00% |
Selected Financial Information
Selected Financial Information Relating To Company's Segments (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Segment Reporting Information [Line Items] | ||||
Net Sales | $ 5,190.1 | $ 4,895.8 | $ 4,357.7 | |
Gross profit | 2,263.5 | 2,214.2 | 1,984 | |
Marketing Expenses | 577.7 | 591.2 | 515 | |
Selling, General and Administrative Expenses | 606.7 | 593.3 | 628.8 | |
Income from Operations | 1,079.1 | 1,029.7 | 840.2 | |
Equity in Earnings (Losses) of Affiliates | 9.4 | 6.7 | 6.6 | |
Income Before Income Taxes | 1,031.7 | 973.8 | 773.7 | |
Identifiable Assets | 7,996.5 | 7,414.5 | 6,657.4 | |
Capital Expenditures | 118.8 | 98.9 | 73.7 | |
Depreciation & Amortization | 219.1 | 189.7 | 176.4 | |
Operating Segments | Consumer Domestic | ||||
Segment Reporting Information [Line Items] | ||||
Net Sales | 3,941.9 | 3,767.6 | 3,302.6 | |
Gross profit | 1,795.8 | 1,801.1 | 1,575.2 | |
Marketing Expenses | 442.1 | 460.6 | 398 | |
Selling, General and Administrative Expenses | 445.3 | 455.6 | 470.1 | |
Income from Operations | 908.4 | 884.9 | 707.1 | |
Equity in Earnings (Losses) of Affiliates | 0 | 0 | 0 | |
Income Before Income Taxes | 861.4 | 832.4 | 645.8 | |
Identifiable Assets | 6,354.5 | 5,819.8 | 5,099.1 | |
Capital Expenditures | 100.3 | 81.8 | 53.9 | |
Depreciation & Amortization | 170 | 142.8 | 131.9 | |
Operating Segments | Consumer International | ||||
Segment Reporting Information [Line Items] | ||||
Net Sales | 912.2 | 828.2 | 756.3 | |
Gross profit | 402.1 | 368.8 | 346.1 | |
Marketing Expenses | 131.1 | 126.9 | 112.9 | |
Selling, General and Administrative Expenses | 135.7 | 128.7 | 151.7 | |
Income from Operations | 135.3 | 113.2 | 81.5 | |
Equity in Earnings (Losses) of Affiliates | 0 | 0 | 0 | |
Income Before Income Taxes | 127.3 | 105 | 74 | |
Identifiable Assets | 1,192.9 | 1,144.5 | 1,110 | |
Capital Expenditures | 8.4 | 7.1 | 9.4 | |
Depreciation & Amortization | 31.1 | 29.6 | 27.1 | |
Operating Segments | Specialty Products | ||||
Segment Reporting Information [Line Items] | ||||
Net Sales | 336 | 300 | 298.8 | |
Gross profit | 112.7 | 104.1 | 110.9 | |
Marketing Expenses | 4.5 | 3.7 | 4.1 | |
Selling, General and Administrative Expenses | 72.8 | 68.8 | 55.2 | |
Income from Operations | 35.4 | 31.6 | 51.6 | |
Equity in Earnings (Losses) of Affiliates | 0 | 0 | 0 | |
Income Before Income Taxes | 33.6 | 29.7 | 47.3 | |
Identifiable Assets | 332.7 | 339.7 | 340.4 | |
Capital Expenditures | 10.1 | 10 | 10.4 | |
Depreciation & Amortization | 15.4 | 14.5 | 14.1 | |
Corporate | ||||
Segment Reporting Information [Line Items] | ||||
Net Sales | [1] | 0 | 0 | 0 |
Gross profit | [1] | (47.1) | (59.8) | (48.2) |
Marketing Expenses | [1] | 0 | 0 | 0 |
Selling, General and Administrative Expenses | [1] | (47.1) | (59.8) | (48.2) |
Income from Operations | [1] | 0 | 0 | 0 |
Equity in Earnings (Losses) of Affiliates | [1] | 9.4 | 6.7 | 6.6 |
Income Before Income Taxes | [1] | 9.4 | 6.7 | 6.6 |
Identifiable Assets | [1] | 116.4 | 110.5 | 107.9 |
Capital Expenditures | [1] | 0 | 0 | 0 |
Depreciation & Amortization | [1] | $ 2.6 | $ 2.8 | $ 3.3 |
[1] | Corporate reflects the following: (A) (B) (C) |
Selected Financial Informatio_2
Selected Financial Information Relating To Company's Segments (Parenthetical) (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | ||
Segment Reporting Information [Line Items] | ||||
Selling, general and administrative expenses | $ 606.7 | $ 593.3 | $ 628.8 | |
Corporate | ||||
Segment Reporting Information [Line Items] | ||||
Selling, general and administrative expenses | [1] | (47.1) | (59.8) | (48.2) |
Corporate | Cost of Sales | ||||
Segment Reporting Information [Line Items] | ||||
Selling, general and administrative expenses | $ 47.1 | $ 59.8 | $ 48.2 | |
[1] | Corporate reflects the following: (A) (B) (C) |
Product Line Revenues from Exte
Product Line Revenues from External Customers (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Segment Reporting Information [Line Items] | |||
Net Sales | $ 5,190.1 | $ 4,895.8 | $ 4,357.7 |
Operating Segments | Consumer Domestic | |||
Segment Reporting Information [Line Items] | |||
Net Sales | 3,941.9 | 3,767.6 | 3,302.6 |
Operating Segments | Consumer Domestic | Household Products | |||
Segment Reporting Information [Line Items] | |||
Net Sales | 2,103 | 2,038.5 | 1,821.7 |
Operating Segments | Consumer Domestic | Personal Care Products | |||
Segment Reporting Information [Line Items] | |||
Net Sales | 1,838.9 | 1,729.1 | 1,480.9 |
Operating Segments | Consumer International | |||
Segment Reporting Information [Line Items] | |||
Net Sales | 912.2 | 828.2 | 756.3 |
Operating Segments | Specialty Products | |||
Segment Reporting Information [Line Items] | |||
Net Sales | $ 336 | $ 300 | $ 298.8 |
Valuation and Qualifying Accoun
Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Allowance for Doubtful Accounts | |||
Valuation And Qualifying Accounts Disclosure [Line Items] | |||
Beginning Balance | $ 3.7 | $ 2.4 | $ 3.1 |
Additions, Charged to Expenses | 0.6 | 1.4 | 0.4 |
Additions, Acquired | 1.9 | 0 | 0 |
Deductions, Amounts Written Off | (0.7) | (0.1) | (1.1) |
Foreign Exchange | 0 | 0 | 0 |
Ending Balance | 5.5 | 3.7 | 2.4 |
Allowance for Cash Discounts | |||
Valuation And Qualifying Accounts Disclosure [Line Items] | |||
Beginning Balance | 6 | 5.1 | 5 |
Additions, Charged to Expenses | 98.4 | 96 | 86.9 |
Additions, Acquired | 0 | 0.4 | 0 |
Deductions, Amounts Written Off | (98.5) | (95.5) | (86.8) |
Foreign Exchange | 0 | 0 | 0 |
Ending Balance | 5.9 | 6 | 5.1 |
Sales Returns and Allowances | |||
Valuation And Qualifying Accounts Disclosure [Line Items] | |||
Beginning Balance | 24.5 | 13 | 12.1 |
Additions, Charged to Expenses | 129.4 | 110.9 | 97.2 |
Additions, Acquired | 0 | 0.4 | 0 |
Deductions, Amounts Written Off | (121.5) | (99.8) | (96.4) |
Foreign Exchange | 0 | 0 | 0.1 |
Ending Balance | $ 32.4 | $ 24.5 | $ 13 |